

US007722869B2

(12) **United States Patent**  
**Burnie et al.**(10) **Patent No.:** **US 7,722,869 B2**  
(45) **Date of Patent:** **May 25, 2010**(54) **ANTIBODY MOLECULES AND NUCLEIC ACIDS**WO 2006/003384 A 1/2006  
WO 2008/132152 11/2008  
WO 2008/132174 11/2008(75) Inventors: **James Burnie**, Cheshire (GB); **Philipp Wechner**, Schwaz (AT)(73) Assignee: **Novartis AG**, Basel (CH)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/150,076**(22) Filed: **Apr. 24, 2008**(65) **Prior Publication Data**

US 2009/0136484 A1 May 28, 2009

(30) **Foreign Application Priority Data**Apr. 27, 2007 (EP) ..... 07107140  
Jul. 27, 2007 (EP) ..... 07113353(51) **Int. Cl.****A61K 39/395** (2006.01)  
**C12P 21/08** (2006.01)  
**C07H 21/04** (2006.01)(52) **U.S. Cl.** ..... **424/135.1**; 424/130.1; 424/133.1;  
424/139.1; 424/141.1; 530/300; 530/350;  
530/388.1; 530/388.5; 536/23.1; 536/23.5;  
536/23.7; 435/69.1; 435/69.7(58) **Field of Classification Search** ..... None  
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**4,732,852 A 3/1988 Cohen et al. .... 435/68  
4,806,465 A 2/1989 Buckley et al. .... 435/7  
5,288,639 A 2/1994 Burnie et al. .... 435/320.1  
5,541,077 A 7/1996 Burnie et al. .... 435/7.31  
5,686,248 A 11/1997 Burnie et al. .... 435/6  
6,583,268 B2 6/2003 Lin  
2003/0180285 A1 9/2003 Burnie ..... 424/130.1**FOREIGN PATENT DOCUMENTS**EP 0 145 333 6/1985  
EP 0 406 029 3/1995  
EP 0 861 892 9/1998  
EP 0 861 893 9/1998  
EP 1 267 925 6/2007  
GB 2240979 8/1991  
WO 86/05400 9/1986  
WO 94/04676 3/1994  
WO 00/61578 10/2000  
WO 01/76627 10/2001  
WO WO0176627 A1 \* 10/2001  
WO WO02/06990 1/2002  
WO 02/069900 A 9/2002  
WO 03/046007 6/2003  
WO 2005/000300 A 1/2005  
WO WO 2005/000300 1/2005  
WO 2005/102386 11/2005  
WO 2005/102386 A 11/2005  
WO 2006/003384 1/2006**OTHER PUBLICATIONS**Proba et al J.Mol. Biol 1997, 265, 161-172.\*  
Rudikoff et al PNAS, 1986, 83:7875-7878.\*  
Casset et al (Biochemical and Biophysical Research Communications, 307:198-205, 2003).\*  
MacCallum et al (J. Mol. Biol., 262,732-745, 1996).\*  
Bendig M. M. (Methods: A Companion to Methods in Enzymology, 1995; 8:83-93).\*  
Colman P. M. (Research in Immunology, 145:33-36, 1994).\*  
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982).\*  
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.\*  
Matthews R C et al., "Human Recombinant Antibody to *HSP90*: A Natural Partner in Combination Therapy", Current Molecular Medicine, vol. 5, No. 4, pp. 403-411, (2005).  
Neckers L et al., "Heat-Shock Protein 90 Inhibitors as Novel Cancer Chemotherapeutics-An update", Expert Opinion on Emerging Drugs, vol. 10, No. 1, pp. 137-149, (2005).  
Anonymous: "Mycograb", Internet Article, Jun. 16, 2006, XP002495190, Retrieved from the Internet: Sep. 9, 2008 URL: <http://web.archive.org/web/20060616021547/http://neutecpharma.com/mycograb.html>.  
EMA: "Refusal CHMP Assessment Report for Mycograb", European Medicines Agency, pp. 1-46, (2007).  
Matthews Ruth C et al., "Preclinical Assessment of the Efficacy of Mycograb, a Human Recombinant Antibody Against Fungal *HSP90*", Antimicrobial Agents and Chemotherapy, vol. 47, No. 7, pp. 2208-2216, (2003).  
Matthews R et al., "Antifungal Antibodies: A New Approach to the Treatment of Systemic Candidiasis", Current Opinion in Investigational Drugs, vol. 2, No. 4, pp. 472-476, (2001).  
International Search Report PCT/EP2008/055006, mailed Sep. 25, 2008.  
WHO Drug Information, vol. 21, No. 1, 2007, International Nonproprietary Names for Pharmaceutical Substances (INN) List 57.  
WHO Drug Information, vol. 20, No. 2, 2006, International Nonproprietary Names for Pharmaceutical Substances (INN) List 95, published Aug. 21, 2006.  
U.S. Appl. No. 10/240,819, filed Oct. 7, 2002, Burnie James.  
U.S. Appl. No. 11/984,177, filed Nov. 14, 2007, Burnie James.  
U.S. Appl. No. 12/076,643, filed Mar. 20, 2008, Burnie James.  
U.S. Appl. No. 12/076,705, filed Mar. 21, 2008, Burnie James.

(Continued)

*Primary Examiner*—Robert B Mondesi  
*Assistant Examiner*—Padma V Baskar  
(74) *Attorney, Agent, or Firm*—Leslie Fischer(57) **ABSTRACT**An scFv peptide comprising a V<sub>H</sub> domain and a V<sub>L</sub> domain linked by an amino acid spacer is disclosed. The V<sub>H</sub> domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64. The V<sub>L</sub> domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 66. The scFv peptide also comprises the substitution or deletion of an amino acid in the V<sub>H</sub> domain at the position corresponding to C<sub>28</sub>.**18 Claims, 21 Drawing Sheets**



## OTHER PUBLICATIONS

- Matthews R et al., "The role of hsp90 in fungal infection", Immunology Today, vol. 13, No. 9, pp. 345-348, (1992).
- Matthews R C et al., "Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis", Immunology, vol. 74, No. 1, pp. 20-24, (1991).
- Burnie, J.P., "Antibiotic Treatment of Systemic Fungal Infections", Current Anaesthesia and Critical Care, vol. 8, pp. 180-183, (1997).
- Vrany, J., "The effect of foliar application of urea on the root fungi of wheat growing in soil artificially contaminated with *Fusarium* spp", Folia Microbiologica, vol. 17, No. 6, pp. 500-504, (1972).
- Granger, D.L., et al., "Macrophage oxidation of L-arginine is linked to fungistatic capability, in Microbial Determinants of virulence and host response", pp. 147-162, E. Ayoub, Ed., American Society of Microbiology, Washington, DC, (1990).
- Matthews et al., "Cloning of a DNA sequence encoding a major fragment of the 47 KD stress protein homologue of *Candida albicans*", FEMS Microbiology Letters, 60:25-30, (1989).
- Matthews et al., "Immunoblot analysis of the serological response in systemic candidosis", Lancet, pp. 1415-1418, (1984).
- Burnie et al., Lancet, "47 KD antigen of *Candida albicans*", pp. 1155, (1985).
- Farrelly et al., "Complete sequence of the heat shock-inducible *HSP90* gene of *Saccharomyces cerevisiae*", The Journal of Biological Chemistry, 259(9):5745-5751, (1984).
- Matthews et al., "Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterisation of serological response to *Candida albicans*", Journal of Clinical Microbiol., 25(2):230-237, (1987).
- Matthews et al., "Characterisation and cellular localisation of immunodominant 47 KDa antigen of *Candida albicans*", Journal of Medical microbiology, 27:227-232, (1988).
- Neale et al., "The immunochemical characterisation of circulating immune complex constituents in *Candida albicans* osteomyelitis by isoelectric focusing, immunoblot and immunoprint", Aust. NZ, J. Med., 17:2011-208, (1987).
- Matthews et al., "Diagnosis of Systemic Candidiasis by an Enzyme-Linked Dot Immunobinding Assay for a Circulating Immunodominant 47-kilodalton Antigen", J. Clin. Microbiol., 26(3):459-463, (1988).
- Dragon et al., "The Genome of *Trypanosoma cruzi* Contains a Constitutively Expressed, Randomly Arranged Multicopy Gene Homologous to a Major Heat Shock Protein", Mol. Cell. Biol. 7(3):1271-1275, (1987).
- Young, R. A. et al., Proc. Nat. Acad. Sci., 80:1194-1198, (1983).
- Lewcock, Anna, Quality, safety issues block Novartis' antifungal approval, <http://www.in-pharmatechnologist.com/news/printNewsBis.asp?id=72292>, p. 1-2, (2006).
- Corrected version of European Search Report for Application No. EP 07075188 dated Sep. 17, 2007.
- Strockbine et al., "Identification and molecular weight characterization of antigens from *Candida albicans* that are recognized by human sera", Infections and Immunity, vol. 43, pp. 715-721, (1984).
- Franklyn et al., "An immunodominant antigen of *Candida albicans* shows homology to the enzyme enolase", Immunol. Cell Biol., 68, pp. 173-178, (1990).
- European Extended Search Report dated Dec. 10, 2008 for EP 07075857.8.
- Burton, D.R. Proceedings of National Acad. Sciences USA, 1991, pp. 11120-11123.
- Orlandi et al., Proceedings of National Acad. Sciences USA, 1991, pp. 11120-11123.
- Winter, G. et al., Nature, vol. 349, 1991, pp. 293-299.
- Huse et al., Science vol. 256, 1989, pp. 1275-1281.
- Maddox et al., J. Exp. Med. vol. 158, 1983, pp. 1211-1226.
- Radding, J.A. et al., Antimicrob. Agents Chemo. Ther, vol. 42, No. 5, 1998, pp. 1187-1194.
- Broad Institute. Coccidioides Group: "Project Info" [Online] Retrieved from the Internet on Nov. 6, 2008: URL:[http://www.broad.mit.edu/annotation/genome/coccidioides\\_group/Info.html](http://www.broad.mit.edu/annotation/genome/coccidioides_group/Info.html).
- Polonelli L et al., "The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections", Medical Mycology, Oxford, GB, vol. 38, No. Suppl. 01, Dec. 30, 2000, pp. 281-292.
- Honegger, H. et al., "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J. Mol. Biol., 309, pp. 657-670 (2001).
- Broad Institute, Data Coccidioides Group: "C. Immitis RS: CIMG\_04729-Heat S" [Online] Retrieved from the Internet on Nov. 6, 2008]: URL:[http://www.broad.mit.edu/annotation/genome/coccidioides\\_group/GeneDetails.html](http://www.broad.mit.edu/annotation/genome/coccidioides_group/GeneDetails.html).
- Anonymous: "Mycograb", Internet article, [online], retrieved from URL: <http://web.archive.org/web/20060616021547>, Jun. 16, 2006; <http://neutecpharma.com/mycograb.html>, Sep. 9, 2008.
- International Search Report PCT/EP2008/055087 dated Oct. 27, 2009.
- Dolezai, O et al., "ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in  $V_L$  to  $V_H$  orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers", Protein Engineering, vol. 13, No. 8, pp. 565-574, (2000).
- Rowlands, H et al., "Human Recombinant Antibody Against *Candida*", The Pediatric Infectious Disease Journal, vol. 25, No. 10, pp. 959-960, (2006).
- Nooney L et al., "Evaluation of Mycograb®, amphotericin B, caspofungin, and fluconazole in combination against *Cryptococcus neoformans* by checkerboard and time-kill methodologies", Diagnostic Microbiology and Infectious Disease, vol. 51, pp. 19-29, (2005).
- Pachl J et al., "A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis", Mycograb and Invasive Candidiasis, vol. 42, pp. 1404-1413, (2006).
- Burnie J et al., "Genetically recombinant antibodies: new therapeutics against candidiasis", Expert Opin. Biol. Ther. vol. 4, No. 2, pp. 233-241, (2004).
- Matthews R et al., "Recombinant antibodies: a natural partner in combinatorial antifungal therapy", Vaccine, vol. 22, pp. 865-871, (2004).
- Hodgetts, S et al., "Efungumab and caspofungin: pre-clinical data supporting synergy", Journal of Antimicrobial Chemotherapy, vol. 61, pp. 1132-1139, (2008).
- Herbrecht R et al., "Mycograb for the treatment of invasive candidiasis", Clin Infect Dis., vol. 43, No. 8, pp. 1083-1084, (2006).
- Excerpts from Briefing Book presented to Paul Ehrlich Institute (PEI) Jul. 2008. Version Jun. 19, 2008, pp. 8-9.
- Questions and Answers on Recommendation for the Refusal of the Marketing Authorisation for Mycograb, European Medicines Agency, London, Nov. 16, 2006, pp. 1-2.
- Semighini C et al., "Dynamic duo takes down fungal villains", PNAS, vol. 106, No. 9, pp. 2971-2972, (2009).
- Cowen L et al., "Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease", PNAS, (2008).
- Karwa, R et al., "Efungumab: A Novel Agent in the Treatment of Invasive Candidiasis", The Annals of Pharmacotherapy, vol. 43, pp. 1818-1823, (2009).

\* cited by examiner










Fig. 2




Fig. 3





Fig. 4




Fig. 5








Fig. 7




Fig. 8



Scaled Estimates					
Nominal factors expanded to all levels					
Continuous factors centred by mean, scaled by range/2					
Term	Scaled Estimate		Std Error	t Ratio	Prob> t
Intercept	10.339265		0.055599	185.96	<.0001*
linker length	0.1344474		0.076476	1.76	0.1168
cysteines	0.0928026		0.052553	1.77	0.1154
arrangement[VH]	-0.209796		0.055923	-3.75	0.0056*
arrangement[VL]	0.2097961		0.055923	3.75	0.0056*




Fig. 9





Fig. 10



- 1. MYC116 from Figure 7 (normalized)
- 2. MYC118 from Figure 7 (normalized)
- 3. MYC119 from Figure 7 (normalized)
- 4. MYC130 from Figure 7 (normalized)
- 5. MYC133 from Figure 7 (normalized)
- 6. MYC135 from Figure 7 (normalized)
- 7. MYC134 from Figure 8 (normalized)
- 8. MYC137 from Figure 8 (normalized)
- 9. MYC138 from Figure 8 (normalized)
- 10. MYC106 from Figure 8 (normalized)
- 11. MYC136 from Figure 8 (normalized)
- 12. MYC139 from Figure 8 (normalized)
- 13. MYC123-ref from Figure 8 (normalized)
- 14. MYC140 from Figure 8 (normalized)

Fig.11








Fig. 12






Fig. 13




Fig. 14






Fig. 15






Fig. 16

- |                                |                      |
|--------------------------------|----------------------|
| 1: MWM Protein <sub>plus</sub> | 2: Reference Biomeva |
| 3: MYC 118, r                  | 10: MYC 118, n-r     |
| 4: MYC 119; r                  | 11: MYC 119 n-r      |
| 5: MYC 130; r                  | 12: MYC 133 n-r      |
| 6: MYC 133; r                  | 13: MYC 134 n-r      |
| 7: MYC 134; r                  | 14: MYC 135 n-r      |
| 8: MYC 135; r                  | 15: MYC 137 n-r      |
| 9: MYC 137, r                  | 16: MYC 130 n-r      |




Fig. 17

- |                                  |
|----------------------------------|
| 1: MWM Protein plus              |
| 2: MYC 106, <sub>origami</sub> r |
| 3: MYC 123; r                    |
| 4: MYC 136; r                    |
| 5: MYC 138; r                    |
| 6: MYC 139; r                    |
| 7: MYC 140; r                    |
| 8: MYC 106, n-r                  |
| 9: MYC 123 n-r                   |
| 10: MYC 123 n-r                  |
| 11: MYC 136 n-r                  |
| 12: MYC 138 n-r                  |
| 13: MYC 139 n-r                  |
| 14: MYC 140 n-r                  |






Fig. 18




Fig. 19






Fig. 20





Fig. 21







Fig. 21 (continued)






Fig. 22






Fig. 22 (continued)




Fig. 22 (continued)






Fig. 22 (continued)



## ANTIBODY MOLECULES AND NUCLEIC ACIDS

This application claims benefit of EP Application No. 07107140.1, filed Apr. 27, 2007 and EP Application No. 07113353.2, filed Jul. 27, 2007, which in their entirety are herein incorporated by reference.

The present invention relates to novel antibody molecules specifically binding to fungal stress protein hsp90, nucleic acids encoding such peptides and pharmaceutical compositions and uses thereof.

An antibody fragment binding to the hsp90 fungal stress protein as well as therapeutic uses of it has been described e.g. in WO01/76627 or WO05/102386. The antibody fragment, also known as Mycograb® (Efungumab), is a fusion protein comprising the  $V_H$  and  $V_L$  domains of immunoglobulin connected by a linker peptide. Such antibody fragments are also known as “single chain variable fragment” (scFv). Mycograb® is produced by fermentation in *E. coli* in the form of inclusion bodies, which are extracted from the cell mass, refolded and subsequently purified by chromatographic steps under denaturing conditions. Characterization studies performed under native conditions have indicated that the efungumab protein has a tendency to form multimers or aggregates (the terms “multimers” and “aggregates” are used interchangeably herein). Such aggregates, in particular high molecular weight aggregates, may not be desirable for therapeutic uses. Thus, for therapeutic uses it may be desirable to eliminate or reduce the high molecular weight aggregates or to control aggregation such that the number of monomers, which a majority of such aggregates contain, are in a certain range, e.g. between 10 and 100 monomers, such as e.g. between 11 and 73 or 26 and 57 monomers.

The present invention now provides improved scFv peptides binding to hsp90 fungal stress protein, which have advantageous properties with respect to e.g. folding properties and/or formation of aggregates. The peptides of the invention are thus particularly useful for therapeutic uses.

According to one aspect of the present invention, there is provided a scFv peptide comprising a  $V_H$  domain and a  $V_L$  domain linked by an amino acid spacer, wherein the  $V_H$  domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64 and the  $V_L$  domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 66 and wherein the scFv peptide comprises an additional feature selected from the group consisting of:

- (a) a substitution or deletion of an amino acid in the  $V_H$  domain at a position corresponding to that selected from the group consisting of: C<sub>28</sub>, I<sub>29</sub>, H<sub>68</sub>, N<sub>85</sub>, C<sub>97</sub> and combinations thereof;
- (b) a substitution or deletion of an amino acid in the  $V_L$  domain at a position corresponding to that selected from the group consisting of: V<sub>2</sub>, V<sub>3</sub>, F<sub>10</sub>, F<sub>14</sub>, A<sub>39</sub>, N<sub>76</sub> and combinations thereof;
- (c) the amino acid spacer comprises the sequence (GGGGS)<sub>n</sub> wherein n is between 4 and 6;
- (d) the  $V_H$  domain further comprises an N-terminal pelB signal sequence comprising the sequence of SEQ ID NO. 68 or a sequence having at least 80% sequence identity thereto;
- (e) the  $V_L$  domain is located at the N-terminal end of the  $V_H$  domain; and
- (f) combinations of features (a) to (e).

It is preferred that the  $V_H$  domain comprises a sequence with at least 90%, 95%, 99% or 100% identity to the sequence of SEQ. ID NO. 64. It is also preferred that the  $V_L$  domain

comprises a sequence with at least 90%, 95%, 99% or 100% identity of the sequence of SEQ. ID NO. 66. It is to be understood that the additional feature is present irrespective of the level of sequence identity. For example, if the additional feature is a substitution of the amino acid at position C<sub>28</sub> then this substitution is present even in embodiments where the  $V_H$  domain comprises a sequence with only 80% sequence identity to SEQ. ID NO. 64.

Conveniently, the substitution of the amino acid in the  $V_H$  domain is selected from the group consisting of: C<sub>28</sub>Y, C<sub>28</sub>S, I<sub>29</sub>S, H<sub>68</sub>R, N<sub>85</sub>S, C<sub>97</sub>Y, C<sub>97</sub>S and combinations thereof. The substitution C<sub>28</sub>Y is particularly preferred.

Advantageously, the substitution of the amino acid in the  $V_L$  domain is selected from the group consisting of: V<sub>2</sub>I, V<sub>3</sub>Q, F<sub>10</sub>S, F<sub>14</sub>S, A<sub>39</sub>K, N<sub>76</sub>S and combinations thereof. Preferably, the scFv peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO. 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 wherein Xaa denotes an amino acid residue other than cysteine and wherein the N-terminal methionine residue may optionally be cleaved off. It is preferred that Xaa denotes a tyrosine residue.

In one embodiment Xaa is Tyr (Y). In another embodiment Xaa is Ala (A), Leu (L), Ile (I), Val (V), Pro (P) or Met (M); in yet another embodiment Xaa is Phe (F) or Try (W); in yet another embodiment Xaa is Gly (G); in yet another embodiment X is Ser (S) or Thr (T); in yet another embodiment Xaa is Glu (E) or Asp (D); in yet another embodiment Xaa is Gln (Q) or Asn (N); in yet another embodiment Xaa is Arg (R), Lys (K) or His (H).

Preferably the scFv peptide further comprises a purification tag, more preferably a sequence of 6 histidine residues at the C-terminus.

In accordance with another embodiment of the present invention, there is provided a scFv peptide consisting of, or consisting essentially of, an amino acid sequence as set forth SEQ ID NO. 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 wherein said peptides may optionally comprise a purification tag such as e.g. a His-Tag (e.g. as set forth in SEQ ID NO. 10, 22 or 34).

The purification Tags typically do not contribute to the therapeutic effect of the molecule and may therefore be removed after purification of the scFv fragments of the present invention.

In accordance with another aspect of the present invention, there is provided a scFv peptide comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62. In one embodiment, there is provided a scFv peptide consisting of, or consisting essentially of, an amino acid sequence as set forth SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 wherein said peptides may optionally also comprise a purification tag such as e.g. a His-Tag (e.g. as set forth in SEQ ID NO. 2, 4 or 20).

As readily appreciated by the skilled person, the first Met residue of the peptides of the present invention may be also cleaved off in vivo, e.g. by *E. coli* MAP (methionine amino peptidase) if expressed in *E. coli*.

The scFv peptides of the present invention comprise two domains linked by an amino acid spacer (the terms “spacer” and “linker” are used interchangeably), e.g. having the amino acid sequence (GGGGS)<sub>n</sub> wherein n is an integer from 1 to 12, e.g. 1, 2, 3, 4 or 5. One of the domains, designated as  $V_H$ , corresponds to the heavy chain part of the antibody fragment (corresponding e.g. to amino acid residues 2 to 122 in the



scFv fragment of amino acid sequence set forth in SEQ ID NO. 2 and SEQ ID NO. 30, or amino acid residues 132 to 152 in SEQ ID NO. 32). The other domain, designated as V<sub>L</sub>, corresponds to the light chain part of the antibody fragment (corresponding e.g. to amino acid residues 138 to 246 in SEQ ID NO. 2, or amino acid residues 138-246 in SEQ ID NO. 12, or amino acid residues 2 to 110 in SEQ ID NO. 32). The VH or the VL domain may be located at the N-terminus of the scFv peptides of the present invention, i.e. the molecules may be linked as follows: VH-linker-VL or VL-linker-VH.

The optional pelB signal sequence results in subcellular localisation of the peptide to the periplasmic membrane, when expressed in *E. coli*, in order to improve solubility of the peptide.

In one embodiment, there is provided a scFv fragment comprising an amino acid sequence as set forth in SEQ ID NO. 30 or 32. In another embodiment, there is provided a scFv peptide consisting of, or consisting essentially of, an amino acid sequence as set forth SEQ ID NO. 30 or 32 wherein said peptides may optionally also comprise a purification tag such as e.g. a His-Tag.

In one aspect, the present invention provides scFv fragments comprising a VH and VL domain and a linker according to the present invention (e.g. as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32 or 34) having at least one amino acid substituted at one or more of the following positions: C29X, 130X, H69X, N86X, C98X, V139X, V140X, F147X, F151X, A176X, N213X, wherein X denotes an amino acid other than as set forth in SEQ ID NO. 2 (the numbering is as set forth in SEQ ID NO. 2 and corresponding amino acid positions in other mutants can be easily determined). In a preferred embodiment, the present invention provides scFv fragments having at least one of the following amino acid substitution: C29Y or C29S, 130S, H69R, N86S, C98Y or C98S, V139I, V140Q, F147S, F151S, A176K, N213S. It is to be appreciated that numbering of amino acids in relation to this aspect includes the N-terminal methionine residue.

In one embodiment, there is provided a scFv fragment comprising an amino acid sequence as set forth in SEQ ID NO. 24, 26 or 28. In another embodiment, there is provided a scFv peptide consisting of, or consisting essentially of, an amino acid sequence as set forth SEQ ID NO. 24, 26 or 28 wherein said peptides may optionally also comprise a purification tag such as e.g. a His-Tag.

The peptides of the present invention are useful as therapeutics. Accordingly, in one aspect of the present invention, there is provided a pharmaceutical composition comprising a scFv peptide according to the present invention, e.g. comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 wherein Xaa is defined as above, in combination with a pharmaceutically acceptable excipient, diluent or carrier. Details of suitable excipients are provided in *Remington's Pharmaceutical Sciences and US Pharmacopoeia*, 1984, Mack Publishing Company, Easton, Pa., USA. Exemplary excipients include pharmaceutical grade (Ph Eur) Urea and L-Arginine (Ph Eur). For example, a typical formulation of an scFv peptide of the invention is 10 mg of pure scFv peptide, 150 mg of pharmaceutical grade (Ph Eur) Urea and 174 mg L-Arginine (Ph Eur) reconstituted in 5 ml water.

An scFv peptide or a pharmaceutical composition of the invention may be administered in a dosage in the range of 0.1 to 10 mg/kg body weight of the patient. A dosage in the range 0.5 to 5 mg/kg body weight is preferred, with a dosage of

around 1 mg/kg being particularly preferred. The pharmaceutical composition may be administered orally.

The peptides of the present invention are useful in the treatment of fungal infections e.g. as disclosed in WO01/76627 or WO05/102386 each of which is hereby incorporated by reference. For example, the peptides of the present invention are useful in the treatment of systemic fungal infections such as invasive candidiasis or invasive aspergillosis or invasive meningitis e.g. virulent *Candida* species *C. albicans*, *C. tropicalis* and *C. krusei* and the less virulent species *C. parapsilosis* and *Torulopsis glabrata*. The peptides of the present invention are also useful in the treatment of infections by *Candida*, *Cryptococcus*, *Histoplasma*, *Aspergillus*, *Torulopsis*, *Mucormycosis*, *Blastomycosis*, *Coccidioidomycosis*, *Paracoccidioidomycosis* organism or *malaria*. Accordingly, the present invention provides a method of treating a patient with a fungal infection comprising administering to the patient an effective amount of a scFv peptide of the present invention, e.g. comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 wherein Xaa is defined as above. The N-terminal Met may optionally be cleaved off.

The peptides of the present invention are particularly useful for combination therapies. Accordingly, in another aspect, the present invention provides a composition or a combined preparation comprising a scFv peptide of the present invention, e.g. comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 (the N-terminal Met may optionally be cleaved off), wherein Xaa is defined as above, and a antifungal agent such as e.g. a polyene antifungal or a echinocandin antifungal or an azole antifungal. Examples of antifungals useful as combination partners of scFv peptides of the present invention include e.g. amphotericin B, derivatives of amphotericin B such as AmBisome, amphotericin-B lipid complex (Abelcet), amphotericin-B colloidal dispersion (Amphocil) and amphotericin-B intralipid emulsion; nystatin; 5-fluorocytosine; caspofungin, anidulafungin, micafungin, LY303366; azoles such as isavuconazole, voriconazole, itraconazole, fluconazole, miconazole, ketoconazole, posaconazole, anidulafungin, micafungin, griseofulvin, terbinafine. Though such combination may be a fixed dose combination, generally, the scFv peptide and its combination partner are not packaged as fixed dose combinations. The combined preparations of the present invention may be for simultaneous, separate or sequential use in the treatment of fungal infections. The peptides of the present invention may also be used in combination with more than one antifungal agent, e.g. with amphotericin B and 5-fluorocytosine, a fingen and Amphotericin B or an echinocandin plus azole.

In another embodiment, the present invention provides a method of treating a patient with a fungal infection comprising administering to the patient an effective amount of a scFv peptide of the present invention, e.g. comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 (the N-terminal Met may optionally be cleaved off), wherein Xaa is defined as above, and at least one of the antifungal agents described above. Preferred combination partners are amphotericin B or derivatives of amphotericin B, caspofungin, anidulafungin, micafungin, voriconazole, itraconazole. The combination partners may be administered simultaneously, separately or sequentially.



5

In one embodiment of the present invention, the fungus causing the infection is resistant or partially resistant against an antifungal combination partner of the peptides of the invention.

The peptides of the present invention are also useful in the treatment of cancer, or a condition involving raised levels of TNF $\alpha$  and/or IL-6 such as autoimmune diseases or sepsis e.g. as disclosed in WO06/003384 or WO07/077,454 (PCT/GB2007/000029) each of which is hereby incorporated by reference. For instance, the peptides of the present invention are useful in the treatment of leukemia such as e.g. lymphoid (lymphocytic) leukaemia (CLL), acute myeloid (myeloblastic) leukaemia (AML), acute lymphoid (lymphoblastic) leukaemia (ALL), chronic myeloid leukaemia (CML), carcinoma of the breast, carcinoma of the colon, prostate, multiple myeloma; or for the treatment of sepsis targeting human hsp90 (WO07/077,454). Accordingly, the present invention provides a method of treating a patient with a cancer disease or a condition involving raised levels of TNF $\alpha$  and/or IL-6 (e.g. autoimmune disease, SIRS or sepsis) comprising administering to the patient an effective amount of a scFv peptide of the present invention, e.g. comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 (the N-terminal Met may optionally be cleaved off), wherein Xaa is defined as above.

In some embodiments, the autoimmune disease is Crohn's disease, rheumatoid arthritis, ulcerative colitis or systemic lupus erythematosus.

The peptides of the present invention are useful for combination therapies with anticancer agents. Examples of suitable anticancer agents include doxorubicin, daunorubicin, epirubicin, herceptin, docetaxel, cisplatin, imatinib (Gleevec®), paclitaxel, cytarabine or hydroxyurea. Accordingly, the present invention provides a composition or a combined preparation comprising a scfv peptide of the present invention, e.g. comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 (the N-terminal Met may optionally be cleaved off), wherein Xaa is defined as above, and a anticancer agent selected from the group consisting of doxorubicin, daunorubicin, epirubicin, herceptin, docetaxel, cisplatin, imatinib, paclitaxel and hydroxyurea. Also provided are methods of treating a patient with a cancer disease comprising administering to the patient in need an effective amount of a scFv of the present invention, e.g. peptide comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 and 62 (the N-terminal Met may optionally be cleaved off), wherein Xaa is defined as above, and at least one of the anticancer agent selected from the group consisting of doxorubicin, daunorubicin, epirubicin, herceptin, docetaxel, cisplatin, imatinib, paclitaxel and hydroxyurea.

In accordance with another aspect of the present invention, there are provided improved nucleic acid molecules encoding scFv peptides as described and improved nucleic acid constructs which are particularly useful for expressing such scFv peptides e.g. in *E. coli*. The nucleic acid constructs of the present invention for instance lead to improved expression of the scFv peptides in *E. coli*, e.g. with respect to homogeneity and titer of the expressed scFv peptide.

Preferably, the nucleic acid molecule further comprises the sequence (taa)<sub>n</sub> located at the 3' end of the sequence encoding the scFv peptide wherein n is 1 or 2.

According to another aspect of the present invention, there is provided a nucleic acid molecule comprising a sequence

6

encoding a V<sub>H</sub> domain comprising a sequence having at least 80% sequence identity to the sequence of SEQ ID NO. 64 and a V<sub>L</sub> domain comprising a sequence having at least 80% sequence identity to the sequence of SEQ ID NO. 66 and further comprising the sequence (taa)<sub>n</sub> located at the 3' end of the sequence encoding the V<sub>H</sub> or V<sub>L</sub> domains wherein n is 1 or 2. The provision of multiple stop codons at the 3' terminus avoids erroneous read-through events.

In another aspect the present invention provides a nucleic acid molecule, e.g. a DNA or RNA molecule, comprising a nucleotide sequence as set forth in SEQ ID NO. 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, or 61 wherein nnn denotes a codon coding for an amino acid other than Cys. For instance, in one embodiment, nnn may code for Tyr such as e.g. TAT. In another aspect, the present invention provides a nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO. 1, 3, 5, 11, 15 or 19. As appreciated by the skilled person, nucleic acid sequences can be readily modified without altering the encoded amino acid sequence. Nucleic acid molecules based on a nucleotide sequence comprising a nucleotide sequence as set forth in SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, or 61. with one or more (e.g. up to 10, 20, 50 or 100) such silent mutations are also comprised within the scope of the present invention. Further encompassed are nucleic acid molecules which have (i) at least 80% identity, preferably at least 90%, 95%, 99% or 100% identity to SEQ. ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, or 61; or (ii) hybridize under high stringency conditions to the nucleic acid molecules having a sequence as set forth in SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, or 61. The term high stringency conditions is readily understood by the skilled person and may refer, e.g., to washing in 6 $\times$ SSC/0.05% sodium pyrophosphate at 37 $^{\circ}$  C. (for 14-base oligos), 48 $^{\circ}$  C. (for 17-base oligos), 55 $^{\circ}$  C. (for 20-base oligos), and 60 $^{\circ}$  C. (for 23-base oligos). Suitable ranges of such stringency conditions for nucleic acids of varying compositions are described in Krause and Aaronson (1991) *Methods in Enzymology*, 200:546-556.

In one embodiment, the present invention provides a vector molecule comprising a nucleotide sequence of a nucleic acid molecule of the invention, e.g. as set forth in SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, or 61. Preferably, such vector molecule is suitable for expressing the nucleic acid molecules as set forth in SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, or 61. in e.g. *E. coli*. Suitable expression vectors are readily known to the skilled person. An example of suitable vector includes for instance pGEX or pET. Another embodiment provides a host cell, e.g. *E. coli*, comprising such a vector molecule.

In another embodiment there is provided a method for producing a scFv peptide of the present invention, e.g. comprising an amino acid sequence as set forth in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60 or 62 (the N-terminal Met may optionally be cleaved off), wherein Xaa is defined as above which comprises culturing a host cell having incorporated therein an expression vector containing under control of suitable transcriptional control elements a nucleic acid sequence of a nucleic acid molecule of the invention e.g. as described in SEQ ID NO. 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57,



59, or 61 under conditions sufficient for expression of said peptides in the host cell, e.g. *E. coli*, thereby causing the production of said peptide; and recovering the peptide produced by said cell.

The percentage "identity" between two sequences is determined using the BLASTP algorithm version 2.2.2 (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-PLAST: a new generation of protein database search programs", *Nucleic Acids Res.* 25:3389-3402) using default parameters. In particular, the BLAST algorithm can be accessed on the Internet using the URL <http://www.ncbi.nlm.nih.gov/blast/>.

#### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a diagram showing schematically the sequence of the wild type Mycograb scFv peptide and Mycograb mutants. Stop codons of the nucleic acid molecules encoding the respective peptides are also shown at the C-terminal end.

FIG. 2 is a diagram showing the principle of the ELISA assay of Example 2.

FIG. 3 is a graph in which the black bars show yield after solubilization with NLS of all investigated mutants. The error bars show the Standard deviation for samples analyzed twice. The white bars are a graphic representation of mass balance after NLS refolds of all investigated mutants. Mutants are ranked according to increasing refolding recovery values.

FIG. 4 shows graphs indicating the recovery after refolding for 5 selected mutants when urea and DTT was used as solubilizing agent (A) and when GuHCl and DTT were used as solubilizing agent (B). White bars: Recovery when mass of protein found in the IB.SOL solution was used for calculation (equ. 1) Black bars: Refolding recovery when mass of protein found in the IB.RES solution is used for calculation.

FIG. 5 is a graph showing the time required for a visible beginning clarification of a solubilization solution after addition of 4% NLS (white bars) and the time required until no further clarification was observed (black bars) for all tested mutants. Mutants are ranked according to the start time in ascending order.

FIG. 6 is a variability chart for the response start of solubilization and indicates number of cysteines, number of linker elements and if the heavy (vh) or light chain (vl) fragment was at the N-terminus. 1: Mutant Myc 106 had the fastest solubilization start but contained 5 cysteines.

FIG. 7 shows chromatograms as an overlay of REF end samples of Mutants MYC 135, Myc 130, Myc 133, Myc 119, Myc 123 wild type and Myc 116.

FIG. 8 shows chromatograms as an overlay of REF end samples of Mutants MYC 134, Myc 137, Myc 138, Myc 106 Myc 136, Myc 123 and Myc 139.

FIG. 9 shows scaled estimates and a prediction profiler of the following parameters: linker length, number of cysteines and Vh/Vl arrangement for the response retention time of mutants. The scaled estimates predict to what extent the retention time would shift when the parameter is increased from centerpoint (the red number in the prediction profiler plot on the x-axis) to a higher level.

FIG. 10 is a plot of linker length versus retention time measured in RP-HPLC (RPC2) for tested mutants. The early retention time of MYC 130 compared with the other mutants is highlighted.

FIG. 11 shows a normalized overlay of all REF.END samples from FIGS. 7 and 8 for estimation of peak area from peak 2.

FIG. 12 shows a RP-HPLC 2 chromatogram overlay of a REF.END sample of MYC 119 solubilized with 8M urea +DTT, 8M urea, 6M GuHCl +DTT and 6M GuHCl dilution was 1:50 with a buffer containing 20 mM Tris, 2 mM cysteine, 1% NLS, pH 9.0.

FIG. 13 is an RPC 2 chromatogram of a REF.END sample of MYC 119 after solubilization with 6M urea and 5 mM DTT and subsequent refolding by a 1:10 dilution.

FIG. 14 is an image of a gel following SDS Page analysis of REF.IM and REF.END sample of MYC 119 after solubilization with 6M urea and refolding by a 1:10 and 1:50 dilution, respectively. Lanes 1-8: non reducing SDS Page, lanes 9-14: reducing SDS Page. R=reducing; n-r=non reducing

FIG. 15 is an RP-HPLC chromatogram overlay (RPC 2) of an inclusion body sample from mutant MYC 119 after solubilization with 6 M urea (black) and 4% NLS (blue).

FIG. 16 shows images of: left gel: Reducing (r) SDS-Page for Mutants MYC 118, 119, 130, 133, 134, 135 and 137; and right gel: Non-reducing (n-r) SDS Page of the same samples

FIG. 17 shows images of: left gel: Reducing SDS-Page for Mutants MYC 106, 123 wt, 136, 138, 139 and 140; and right gel: Non-reducing SDS Page of the same samples

FIG. 18 is an overlay of SEC HPLC 0.5% NLS chromatograms of REF.END samples for the mutants Myc 118, Myc 119, Myc 130, Myc 133 and Myc 135. IBs from these mutants were isolated at bench scale.

FIG. 19 is an overlay of SEC HPLC 0.5% NLS chromatograms of REF.END samples for the mutants Myc 134, Myc 136, Myc 137, Myc 138, Myc 139, Myc 140, Myc 106 and Myc 123 wild type. IBs from these mutants were isolated in the pilot plant.

FIG. 20 shows a scatter plot and linear regression (continuous line) of measured MW versus theoretical MW of REF.END samples for all mutants. The 95% confidence interval for the fit is also shown (dashed line). The dot at top left shows MYC 130. The dots within the dashed lines are within the 95% CI and therefore not significantly different from the wildtype. The dots below both dashed lines represent mutants with lower average MW than predicted and the dots above both dashed lines represent mutants where a higher average MW was measured than predicted.

FIG. 21 shows SEC-HPLC (formulation) chromatograms for REF.END samples of Myc 119, Myc 106-origami, Myc 123 wt and Myc 137 after UFDF against 50 mM Tris, pH 9.0 buffer. Samples were taken after each volume reconstitution. Sample prior to UFDF treatment (5), after 1<sup>st</sup> buffer exchange step (2), 2<sup>nd</sup> buffer exchange step (3), 3<sup>rd</sup> (4) and last (5) step.

FIG. 22 shows RP-HPLC 2 chromatograms of REF.IM, REF.3T and REF. END samples for all tested mutants:

#### BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO. 1 is Myc123  
 SEQ ID NO. 2 is the peptide sequence encoded by SEQ ID NO. 1  
 SEQ ID NO. 3 is Myc102, Mycograb-6H-TAA  
 SEQ ID NO. 4 is the peptide sequence encoded by SEQ ID NO. 3  
 SEQ ID NO. 5 is Myc101, Mycograb-TAA  
 SEQ ID NO. 6 is the peptide sequence encoded by SEQ ID NO. 5  
 SEQ ID NO. 7 is MycC29X-TAA, e.g.: Myc105, MycC29Y-TAA  
 SEQ ID NO. 8 is the peptide sequence encoded by SEQ ID NO. 7



SEQ ID NO. 9 is MycC29X-6H-TAA, e.g.: Myc106, MycC29Y-6H-TAA, Myc113, MycoC29S-6H-TAA  
 SEQ ID NO. 10 is the peptide sequence encoded by SEQ ID NO. 9  
 SEQ ID NO. 11 is Myc107, Myco-4-TAA  
 SEQ ID NO. 12 is the peptide sequence encoded by SEQ ID NO. 11  
 SEQ ID NO. 13 is MycoC29X-4-TAA, e.g.: Myc108, MycoC29Y-4-TAA; Myc114, MycoC29S-4-TAA  
 SEQ ID NO. 14 is the peptide sequence encoded by SEQ ID NO. 13  
 SEQ ID NO. 15 is Myc109, N-Myco-4-TAA  
 SEQ ID NO. 16 is the peptide sequence encoded by SEQ ID NO. 15  
 SEQ ID NO. 17 is N-MycoC29X-4-TAA, e.g.: Myc 10, N-MycoC29Y-4-TAA  
 SEQ ID NO. 18 is the peptide sequence encoded by SEQ ID NO. 17  
 SEQ ID NO. 19 is Myc111, N-Myco-6H-TAA  
 SEQ ID NO. 20 is the peptide sequence encoded by SEQ ID NO. 19  
 SEQ ID NO. 21 is N-MycoC29X-6H-TAA, e.g.: Myc112, N-MycoC29Y-6H-TAA  
 SEQ ID NO. 22 is the peptide sequence encoded by SEQ ID NO. 21  
 SEQ ID NO. 23 is Myc115, MycYSSS  
 SEQ ID NO. 24 is the peptide sequence encoded by SEQ ID NO. 23  
 SEQ ID NO. 25 is Myc116, MycYSIQSS  
 SEQ ID NO. 26 is the peptide sequence encoded by SEQ ID NO. 25  
 SEQ ID NO. 27 is Myc117, MycSIQKS  
 SEQ ID NO. 28 is the peptide sequence encoded by SEQ ID NO. 27  
 SEQ ID NO. 29 is Myc118, VH-2Bam-2VL  
 SEQ ID NO. 30 is the peptide sequence encoded by SEQ ID NO. 29  
 SEQ ID NO. 31 is Myc119, VL-2Bam-2VH  
 SEQ ID NO. 32 is the peptide sequence encoded by SEQ ID NO. 31  
 SEQ ID NO. 33 is Myc145, MycC98X-6H-TAA  
 SEQ ID NO. 34 is the peptide sequence encoded by SEQ ID NO. 33  
 SEQ ID NO. 35 is Myc129 (MycYSRIQSS)  
 SEQ ID NO. 36 is the peptide sequence encoded by SEQ ID NO. 35  
 SEQ ID NO. 37 is Myc130 (MycYSRSIQSSKS)  
 SEQ ID NO. 38 is the peptide sequence encoded by SEQ ID NO. 37  
 SEQ ID NO. 39 is Myc133  
 SEQ ID NO. 40 is the peptide sequence encoded by SEQ ID NO. 39  
 SEQ ID NO. 41 is Myc134  
 SEQ ID NO. 42 is the peptide sequence encoded by SEQ ID NO. 41  
 SEQ ID NO. 43 is Myc135  
 SEQ ID NO. 44 is the peptide sequence encoded by SEQ ID NO. 43  
 SEQ ID NO. 45 is Myc136  
 SEQ ID NO. 46 is the peptide sequence encoded by SEQ ID NO. 45  
 SEQ ID NO. 47 is Myc137  
 SEQ ID NO. 48 is the peptide sequence encoded by SEQ ID NO. 47  
 SEQ ID NO. 49 is Myc138  
 SEQ ID NO. 50 is the peptide sequence encoded by SEQ ID NO. 49

SEQ ID NO. 51 is Myc139  
 SEQ ID NO. 52 is the peptide sequence encoded by SEQ ID NO. 51  
 SEQ ID NO. 53 is Myc140  
 SEQ ID NO. 54 is the peptide sequence encoded by SEQ ID NO. 53  
 SEQ ID NO. 55 is Myc141  
 SEQ ID NO. 56 is the peptide sequence encoded by SEQ ID NO. 55  
 SEQ ID NO. 57 is Myc142  
 SEQ ID NO. 58 is the peptide sequence encoded by SEQ ID NO. 57  
 SEQ ID NO. 59 is Myc143  
 SEQ ID NO. 60 is the peptide sequence encoded by SEQ ID NO. 59  
 SEQ ID NO. 61 is Myc144  
 SEQ ID NO. 62 is the peptide sequence encoded by SEQ ID NO. 61  
 SEQ ID NO. 63 is the nucleotide sequence encoding the heavy chain of the wild type Myc123 scFv peptide.  
 SEQ ID NO. 64 is the peptide sequence encoded by SEQ ID NO. 63  
 SEQ ID NO. 65 is the nucleotide sequence encoding the light chain of the wild type Myc123 scFv peptide.  
 SEQ ID NO. 66 is the peptide sequence encoded by SEQ ID NO. 65.  
 SEQ ID NO. 67 is the nucleotide sequence of the pelB signal sequence.  
 SEQ ID NO. 68 is the peptide sequence encoded by SEQ ID NO. 67.  
 SEQ ID NO. 69 is the epitope from Candidal hsp90 for which the scFv peptide of SEQ ID NO. 2 (Mycograb) is specific.  
 SEQ ID NO. 70 is the epitope of a scrambled peptide used in the binding assay of Example 2.

## EXPERIMENTAL

### Example 1

*E. coli* host cells are transformed with the expression vector and cultivated in submers culture. At suitable OD600, expression of scFv is induced by derepression or activation of the inducible promoter (i.e. tac, trc or T7-lac promoter). This induction leads to accumulation of scFv in the host cell, resulting in production of insoluble inclusion bodies mainly made of aggregated scFv. After a suitable expression period, cells are harvested by centrifugation and disrupted. The insoluble inclusion bodies are subsequently isolated by gravimetric means.

The DNA sequences set forth in SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59 or 61 are inserted into an expression vector suitable for *E. coli* (i.e. pET). The protein is expressed in a *Escherichia coli* host and then purified by affinity chromatography. Standard molecular biology protocols are employed (see, for example, Harlow & Lane, supra; Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Sambrook, J. & Russell, D., 2001, Molecular Cloning: A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor).

After intracellular expression the scFv peptides are accumulated in the form of inclusion bodies within the *E. coli* cells. For purification, inclusion bodies are isolated and the product is extracted by solubilization and refolding. Purifica-



## 11

tion to over 95% purity is achieved by ion exchange chromatography and immobilized metal affinity chromatography (IMAC).

## Example 2

## ELISA Activity Assay

## 1. Summary

The binding activity of MYC123 (“wild type” Mycograb) and mutant Mycograb peptides was detected in an ELISA using the peptide epitope of hsp 90 as antigen. Mycograb or mutant Mycograb became bound to biotinylated peptide, which in turn was bound to streptavidin-coated microtitre plates. A scrambled peptide was used as a control sequence. Detection was accomplished using a peroxidase conjugated anti-His antibody, which binds to the His region of the MYC 123 protein. The peroxidase reacted with the ABTS substrate to produce a green substance, the absorption of which was measured at 405 nm. The absorption at 405 nm is proportional to the activity of MYC123 in the solution. The activity was determined from the 6-point calibration curve for a reference standard and was indicated as % activity compared with the reference.

The principle of the ELISA is depicted in FIG. 2 in which Streptavidin 1 is coated on a plate and is bound to biotin 2. The biotin 2 is, in turn, bound to the Hsp 90 peptide 3 which is located in the Hsp90 binding site 4 of the MYC123 scFv peptide 5. The scFv peptide 5 has a His tag 6 to which becomes bound the Anti-His-Peroxidase detection antibody 7.

## 2. Principle and Source of Procedure

The ELISA utilised was a direct detection assay where Mycograb or mutant Mycograb was captured using a streptavidin surface microplate coated with a biotinylated antigenic peptide (Biotin-NKILKVIRKNIVKK—epitope sequence from candidal Hsp90). The presence of Mycograb or mutant Mycograb was then detected using an anti-His tag antibody conjugated to horse radish peroxidase. ABTS, a substrate for the horse radish peroxidase, was then added to the wells, and the concentration of Mycograb present was proportional to the absorbance measured at 405 nm. The activity of samples of Mycograb or mutant Mycograb was determined directly from a standard curve generated using the pre-existing Mycograb drug product reference material.

## 3. Materials

## 3.1 Equipment

Streptawell High Bind microtitre plates were supplied by Roche (Cat No. 11989685001). Assays were performed using a Bio-Rad Model 680 microplate reader. Hardware control was performed using the Microplate Manager Software version 5.2.1 (Bio-Rad, USA). Data analysis was performed using Microsoft Excel.

## 3.2 Chemicals and Reagents

## 3.2.1 Chemicals

All chemicals were of analytical grade unless otherwise stated.

Tris . . . Sigma T6791

Bovine Serum Albumin . . . Sigma A7030

Concentrated Hydrochloric acid . . . Sigma 32033-1

Phosphate Buffered Saline Tablets . . . Sigma P4417

Tween 20 . . . SigmaUltra P7949

Anti-His tag antibody HRP conjugate Sigma A7958

ABTS . . . Sigma A3219

## 12

Biotin-NKILKVIRKNIVKK (SEQ. ID NO: 69) Pepceuticals, UK

Biotin-SFKWGVTTLSYFPK (SEQ. ID NO: 70) Pepceuticals, UK

5 Water, Milli-Q water 18.2M $\Omega$ filtered 0.22  $\mu$ m pore size.

## 3.2.2 Reagents

Blocking Buffer Stock 1 (5% w/v BSA in Milli-Q water)  
BSA . . . 2.5 g

10 Weighed out 2.5 g of BSA and added to 50 mL of Milli-Q water. Store at 4° C. for 1 week.

1M Tris Buffer pH 7.8

Tris . . . 121.24 g

15 Weighed out 121.24 g Tris and dissolved in 950 ml Milli-Q water with stirring. Checked and adjusted pH with drop-wise addition of Concentrated Hydrochloric Acid until pH was 7.8. Made up to 1 liter with Milli-Q water. Filtered through a 0.22  $\mu$ m filter (Sartorius) and stored at room temperature for up to 1 month.

20 Sample Diluting Buffer (20 mM Tris pH 7.8 0.1% w/v BSA)

1 mL of 1M Tris stock solution was added to 48 ml of Milli-Q water and 1 ml of Blocking buffer Stock 1 solution. Made fresh for each experiment.

25 Wash Buffer (PBS+Tween 20 0.1% v/v)

Dissolved 5 PBS tablets in 900 mL of Milli-Q water, added 1 mL of Tween 20, stirred until tablets had dissolved and made up to 1000 mL with Milli-Q water. Stored at 4° C. for up to 1 week.

30 Blocking Buffer Stock 2 (Wash Buffer+5% w/v BSA)

BSA . . . 2.5 g

Weighed out 2.5 g of BSA and dissolved in 50 mL of Wash Buffer. Stored at 4° C. for 1 week.

35 Peptide Diluting Buffer (PBS+0.1% v/v Tween 20+0.1% w/v BSA)

1 mL of Blocking buffer Stock 2 was added to 49 mL of Wash buffer. Made fresh for each experiment.

Antigenic Peptide Solution

Biotin-NKILKVIRKNIVKK peptide . . . 10 mg.

40 A 2 mg/ml solution of the custom synthesised antigenic peptide solution was made up by weighing out 10 mg of peptide and dissolving it in 5 ml of Milli-Q water. 50-100  $\mu$ l aliquots were dispensed into 1.5 ml Eppendorf tubes and stored frozen at -80° C. for up to one year.

45 Antigenic Peptide Working Solution (4  $\mu$ g/mL Peptide in Peptide Diluting Buffer)

25  $\mu$ L of Antigenic peptide solution (2 mg/mL) was added to 12.475 mL of Peptide Diluting Buffer to give a 4  $\mu$ g/mL solution. Made fresh for each experiment.

## 3.2.3 Sample Preparation

Control Article

50 Resuspended 1 $\times$ 10 mg Mycograb reference batch (BN270603) in 5 ml of Milli-Q water, mixed gently to ensure all the powder in the vial was incorporated and dissolved. Centrifuge at 13,000 rpm for 5 minutes to remove any particulate matter. The protein concentration of this solution was then determined according to the standard UV protein concentration procedure.

60 Test Article

Resuspended 1 $\times$ 10 mg Mycograb or mutant Mycograb test material in 5 ml of Milli-Q water, and processed in an identical fashion to the Control Article.

Calibration Curve Standards

65 Control Article material was diluted in Sample Diluting buffer to give 5 mL of a 5  $\mu$ g/mL top concentration sample. This solution was then used to generate two-fold serially



diluted samples each in a final volume of 2 mL over a concentration range of 5-0.156 µg/mL.

#### 4. Procedure

1. An aliquot of the 2 mg/ml stock solution of antigenic peptide was removed from the freezer and diluted 1:500 (25 µl peptide in 12.5 ml buffer) with PBS buffer containing 0.1% (w/v) BSA and 0.1% (v/v) Tween 20 to generate a working solution of 4 µg/ml peptide. A 96 well high bind StreptaWell plate (Roche) was coated from rows B-H with 100 µl of 4 µg/ml biotin-NKILKVIRKNIVKK peptide in 0.1% (w/v) BSA PBS-0.1% (v/v) Tween 20. 100 µl per well of 0.1% (w/v) BSA PBS-0.1% (v/v) Tween 20 were added to all wells in Row A. The plate was then stored overnight at 4° C.
2. The plate wells were then washed 3×30 sec with 200 µl of PBS 0.1% (v/v) Tween 20 buffer on a Thermo WellWash AC.

reached 1.3 AU. The concentration of Mycograb® was proportional to the absorption at A405 nm.

7. The A405 nm absorbance results for the reference material were transferred into an Excel spreadsheet and a 6-point second order calibration function  $y=a+bx+cx^2$  was plotted from the reference sample A405 nm minus blank versus concentration of Mycograb® in µg/ml with a correlation coefficient of  $\geq 0.99$ . If an observed 'hook' effect existed, the highest concentration point was removed from the graph, leaving a 5-point calibration curve. Two individual well outliers (as determined by eye) per plate was removed from the data analysis under some circumstances, provided that there is no more than one outlier per triplicate measurement. Percentage activity was calculated using non-linear regression analysis to calculate apparent concentrations in the samples using the appropriate absorbance means.

The ELISA results obtained during the study are shown in Table 1.

TABLE 1

Sample information				Bioassay data	
				ELISA	ELISA
No.	Sample	Sample info	Buffer composition	Site 1 [%]	Site 2 [%]
1	MYC123 WT DFR	Wild type	50 mM Tris, pH 9.0	71	95
2	DP (#140602)	Wild type	0.5 M urea, 0.2 M L-arginine pH 9.5	90	78
3	MYC123 WT DOW.FT	Wild type	50 mM Tris, 1 M sucrose, ~0.2% Tween20, 3 mM DTT, pH 3.0	135	130
4	MYC123 WT DOW.FT	Wild type	50 mM Tris, 3 mM DTT, pH 9.0	85	131
5	MYC C28Y DFR	C28Y	50 mM Tris, pH 9.0	76	91
6	MYC C28Y DOW.FT	C28Y	50 mM Tris, 3.3 mM DTT, pH 9.0	79	98

3. Mycograb and mutant Mycograb samples were prepared prior to loading by diluting down to 5 µg/ml in 20 mM Tris buffer pH 7.8, 0.1% (w/v) BSA from the resuspended Mycograb vial stock solution. Mycograb® samples were then prepared from this initial 5 µg/ml solution by serial dilution ×2 down to 0.15625 µg/ml with 20 mM Tris buffer pH 7.8, 0.1% (w/v) BSA. All the individual dilutions were performed in either 1.5 ml Eppendorf tubes (VWR Cat No 211-2139) or 7 ml Bijoux containers (VWR Cat. No. 215-0328), depending on the amount required for the experiment. 100 µl of each dilution sample was then loaded onto the plate in triplicate. A control set of blank wells containing 100 µl 20 mM Tris pH 7.8, 0.1% (w/v) BSA was also included in Row H.

4. The plate was left at room temperature for 1 hour and the wells then washed 3 times with PBS-0.1% (v/v) Tween 20 as described in step 2.

5. 100 µl of mouse monoclonal Anti-His HRP conjugate (Sigma A7058) was loaded into each well at a concentration of 1:2000 in 0.1% (w/v) BSA PBS-0.1% (v/v) Tween 20 and left for 1 hour at room temperature.

6. Wells were then washed as described above and the bound Mycograb® detected by the addition of 100 µl of ABTS® reagent. The colourimetric development was read at 405 nm with readings taken when the absorbance of the highest concentration samples in the second calibration curve

Samples 1 and 3-6 are process intermediates (not final drug substance) obtained after prepurification of inclusion bodies, refolding and removal of detergent NLS (by Dowex chromatography or diafiltration). Sample 2 is an original wild type drug product produced by Biomeva/Thymoorgan and used in Phase III trials. The specification for the original drug product was 75-125% of the reference standard. All samples were judged as active (binding).

#### Example 3

##### Minimum Inhibitory Concentration Determination of *Cryptococcus neoformans*

#### Summary

In the MIC assay the antimycotic activity of MYC123, using *Cryptococcus neoformans* as model organism, was determined. This assay measures antifungal activity and may mimic the action of MYC 123 in the clinical setting.

The MIC of MYC 123 was determined by broth micro dilution according to the National Committee for Clinical Laboratory Standards document M27-A2 (2002). Briefly: RPMI medium was inoculated with  $10^3$  CFU/ml of *C. neoformans*. MYC123 was added in decreasing concentrations to the medium (1024 µg/ml, 512 µg/ml, 256 µg/ml . . .). The MIC plates were incubated at 37° C. for 72 h. The endpoints



were determined as the concentration to produce optically clear wells (MIC-0) and the concentration resulting in a prominent decrease in turbidity ( $\geq 50\%$  growth inhibition, MIC-2) compared with the growth control.

#### Method

##### Pre-Assay Preparation

Safety cabinet: A SAB plate was inoculated with *C. neoformans* and incubated for 48-72 hr at 35° C. The plate was sealed with parafilm.

#### Bench:

RPMI was prepared. Antifungal agents were prepared according to NCCLS methodology (M27-A2)—total of 11 concentrations in RPMI growth medium. Concentrations were at 2× the final concentration required for single MIC

#### MIC Plate

In a U-shaped 96-well plate—100  $\mu$ l of the highest drug concentration to be tested (2× required concentration) was added to well 1 of rows A and B (assay done in duplicate). This was repeated across the columns on the plate with descending concentrations e.g. next concentration well 2 of rows A+B, next concentration well 3 of rows A+B. Well 12 contained growth medium only.

Safety Cabinet Inoculum Preparation—Direct colony suspension. A direct colony suspension of *Cryptococcus neoformans* was made from a 48-72 hr old plate into RPMI medium. This was adjusted to 0.5 MacFarlands standard (approx  $1 \times 10^6$ – $5 \times 10^6$  cfu/ml). A 1:50 dilution was made. A further 1:20 dilution (approx  $1 \times 10^3$ – $5 \times 10^3$  cfu/ml, 2× inoculum required) was made

Safety cabinet: Plate inoculation. The plate was worked from well 12 to well 1. This avoided drug carryover. 100  $\mu$ l of inoculum suspension was pipetted into each well (final inoculum  $(0.5 \times 10^3$ – $2.5 \times 10^3$  cfu/ml). Plates were sealed with parafilm.

#### Incubation

The MIC plates were incubated at 37° C. for 72 hrs. To check the inoculum, the inoculum suspension were serially diluted and 101 of the dilutions were plated out onto a SAB plate and incubated at 37° C. for 72 hrs.

#### Reading Results

Using a reading mirror; growth was compared with that of the 'no-drug' control (well 12) and growth scored as follows:

0—optically clear

1—slightly hazy

2—prominent decrease in growth (approx 50%)

3—slight reduction in turbidity

4—no reduction in turbidity

MIC results obtained during the study as shown in Table 2

TABLE 2

Sample information				Bioassay data MIC
				25 Feb. 2008/
No.	Sample	Sample info	Buffer composition	29 Feb. 2008 [ $\mu$ g/ml]
1	MYC123 WT DF.R	Wild type	50 mM Tris, pH 9.0	128
2	DP (#140602)	Wild type	0.5 M urea, 0.2 M L-arginine pH 9.5	64
3	MYC123 WT DOW.FT	Wild type	50 mM Tris, 1 M sucrose, ~0.2% Tween20, 3 mM DTT, pH 3.0	16
4	MYC123 WT DOW.FT	Wild type	50 mM Tris, 3 mM DTT, pH 9.0	64

TABLE 2-continued

Sample information				Bioassay data MIC
				25 Feb. 2008/
No.	Sample	Sample info	Buffer composition	29 Feb. 2008 [ $\mu$ g/ml]
5	5	MYC C28Y DF.R	C28Y 50 mM Tris, pH 9.0	64
6	6	MYC C28Y DOW.FT	C28Y 50 mM Tris, 3.3 mM DTT, pH 9.0	64
15		Reference 070602	0.5 M urea, 0.2 M L-arginine pH 9.5	128/64
15		Buffer FB	0.5 M urea, 0.2 M L-arginine pH 9.5	512 or 256
20		Buffer Tris	50 mM Tris, pH 9.0	>512
20		Buffer 6	50 mM Tris, 3 mM DTT, 1 M sucrose, 0.2% Tween20, pH 3.0	16

Samples 1 and 3-6 were process intermediates (not final drug substances) obtained after prepurification of inclusion bodies, refolding and removal of detergent NLS (by Dowex chromatography or diafiltration). Sample 2 was an original wild type drug product produced by Biomeva/Thymoorgan and used in Phase III trials.

The MIC results obtained for the samples were compared with the results obtained for the corresponding buffer. All the samples were regarded active in comparison to the Reference 070602 besides sample 3. Sample 3 and the Buffer 6 gave the same results demonstrating that the buffer without MYC123 was toxic for the test organism. Values for the samples 1 and 4-6 were far from the values for Buffer Tris which indicates an increased reliability of the data.

#### Example 4

#### Summary

The aim of the Mycograb mutants was to obtain a mutant scFv peptide with improved structural properties compared with the wild type Mycograb. It was believed that through point mutations, especially the replacement of free cysteine by tyrosine, aggregation and formation of incorrect disulfide bonds during down stream processing should be reduced. It was also believed that exchanging the orientation of the heavy chain fragment with the light chain fragment and removing the HIS-Tag is beneficial for formation of a native 3D structure of the Mycograb molecule.

After cloning, the constructs were sequenced prior to fermentation. The fermentation was scaled up to deliver enough material for inclusion body (IB) isolation and for further downstream processing. The expression constructs of the mutants were purified according to the adapted Biomeva process until the refold end step.

The physical parameters of a range of mutant Mycograb peptides was tested as set out in Examples 5 to 12.

An overview of the mutants tested and their mutations is given in Table 3. The wild type was included in the studies for comparison reasons.



TABLE 3

Name and structural properties of the 12 investigated Mycograb mutants and the wild type (myc 123)					
MUTANT	HIS tag	Linker VH-VL		cysteines	additional mutations
		length	alignment		
MYC 118	NO	4X	VH N-terminal	5	
MYC 119	NO	4X	VL N-terminal	5	
MYC 130	NO	3X	VH N-terminal	4	C29Y, I30S, H69R, N86S, V139I, V140Q F147S, F151S, A176K, N213S
MYC 133	NO	5X	VH N-terminal	5	
MYC 135	NO	5X	VL N-terminal	5	
MYC 134	NO	6X	VH N-terminal	5	
MYC 137	NO	4X	VH N-terminal	4	C29Y, I30S
MYC 138	NO	5X	VH N-terminal	4	C29Y, I30S
MYC 106 origami	YES	3X	VH N-terminal	4	oxidatives cytoplasm
MYC 136	NO	6X	VL N-terminal	5	
MYC 139	NO	6X	VH N-terminal	4	C29Y, I30S
MYC 123_Wt	YES	3X	VH N-terminal	5	
MYC 140	NO	4X	VL N-terminal	4	C29Y, I30S

The methodology used in the test assays will now be described.

#### Inclusion Body (IB) Isolation

4 L of fermentation broth obtained in LVA (Laborversuchsanstalt) from shake flask culture of Mutants Myc 118, 119, 130, 133 and Myc 135 were disintegrated with a high pressure homogenizer (LAB 40-15 RBF1) in RPP4 at 700 Bar for 2 cycles of 15 min each. The IBs were separated from the cell debris at lab scale with a bottle centrifuge at 10000 rpms for 20 min at 4° C. IBs were washed twice with water for laboratory use (WFL) and afterwards, a 20% (w/v) suspension in WFL was prepared. The suspension was stored in aliquots at -20° C.

IBs from mutants Myc 134, 137, 138, 106, 136, 139, 140 and Myc 123 (wt) were isolated at pilot scale in RPP4 because fermentation of these mutants was done at 30 L scale in bioreactors. IBs were separated from cell debris with a disc stack centrifuge. A 20% suspension (w/v) in WFL was prepared. This suspension was stored in aliquots at -20° C.

#### Solubilization

Solubilization with NLS (according to adapted Biomeva process). Solubilization of the 20% IB suspension was done by dilution with WFL to a protein concentration of 8 mg/ml followed by a 1:2 dilution with 100 mM Tris/Base, 4% NLS, pH 9.0 buffer. The solution was stirred at room temperature in a beaker until clarification but at least for 30 min. The time until start and end of clarification was recorded.

Alternative Solubilization with Urea, GuHCl, DTT. The alternative solubilization strategy was performed by a 1:10 dilution of a respective volume of 20% IB suspension with 20 mM Tris 8M Urea+/-5 mM DTT or 20 mM Tris, 6M GuHCl+/-5 mM DTT both at pH 9.0. The resulting concentration of urea and GuHCl was 7.2M and 5.2M respectively, due to the volume of the IB suspension solution.

#### Refolding of Solubilized IB's

Refolding with NLS. The refold was done by 1:4 dilution of the solubilization solution with a 50 mM Tris/Base buffer. The final concentration of NLS was 0.5%. Refolding was initiated by addition of 50 µM CuCl<sub>2</sub>. Samples were taken and immediately submitted for RPC2 analysis prior and after CuCl<sub>2</sub> addition, then approximately 24, 48, 72 and 96 hours after CuCl<sub>2</sub> addition.

25 Refolding after solubilization with Urea, GuHCl. Refolding of a Mycograb solution after solubilization with 8M urea or 6M GuHCl+/-DTT was performed by 1:50 dilution with a buffer containing 20 mM Tris/Base, 1% NLS and 2 mM Cystin at pH 9.0.

30 For some mutants, dilution of a Mycograb solution after solubilization with urea by 1:10 with a buffer containing 20 mM Tris/Base, 0.5M L-arginine and 2 mM Cystin at pH 9.0 was also performed.

35 The refold solution was stirred for 96 hrs at 4° C. or 24 hrs at RT, respectively.

#### Refolding Kinetics

40 A refold kinetic was recorded for mutant Myc 119 in order to determine the required refolding time. A sample of a 20% IB suspension of Myc119 was solubilized as described above. Refolding was performed as described above, but samples were taken at respective time intervals and analyzed by RPC 2.

45 NLS removal by UF/DF from refolding solution. Mutants Myc119, Myc 137, Myc 106 and Myc 123 (wt) were solubilized and refolded as described above. After refolding, a buffer exchange of REF.END solution was performed with an Amicon stir cell with 10 kDa molecular weight cut-off. NLS concentration after each turn over volume was determined with RP-HPLC. 50 ml of REF.END solution were concentrated to 25 ml and then filled up again to 50 ml with diafiltration buffer. This procedure was carried out 4 times. Aggregation tendency after NLS removal was measured with SEC-HPLC running with formulation buffer.

#### SDS Page Analysis

50 SDS Page was performed using NuPAGE 4-12 BisTris gels and MOPS as running buffer. The run time was 65 minutes at 200 volt. A mass of 0.2-0.4 µg Mycograb was applied on each lane. After electrophoresis, the gels were stained with silver. For reducing SDS Page, 100 mM DTT was added to the sample.

#### Results

65 The expression construct of the mutants was analyzed at different stages in the down stream procedure with the analytical methods listed in Table 4:



TABLE 4

Code and description of process intermediates and the respective analytical assay		
CODE	Intermediate description	Analytical method
IB.RES	Resuspension of IB's (20% w/v)	RPC 1
IB.SOL	Solubilized IB's	RPC 1, RPC 2
REF.IM	Refold intermediate prior to CuCl <sub>2</sub> addition	RPC 1, RPC 2
REF.END	Refold solution, endpoint	RPC 1, RPC 2, SEC 0.5% NLS, SDS PAGE red/non red, Pep-map, denat. SEC

Table 5 gives a description of the analytical methods listed in Table 4 that were used for evaluation of the mutants. A comment is included describing the specificity of the particular assay.

TABLE 5

Analytical method, the respective response and Unit of Measurement (UoM) for the assays used to evaluate the mutant samples.			
Analytical method	Response	UoM	Comment
RPC 1	total protein mass	mg/ml	This assay is not specific for Mycograb Sample is dissolved with SDS, DTT and urea
RPC II	chromatogram	$t_{R(monomer)}$ [min]	Assay can only be evaluated by overlay of chromatograms. Shift of the 'monomeric peak' indicates refolding
SEC 0.5% NLS	average molecular weight	kDa	For samples containing 0.5% NLS. RT of peak maximum is correlated to MW. Broad elution peak from 43-900 kDa
SDS Page reducing	Monomeric/Dimeric band; Impurity content	band	Non-covalent aggregates are dissolved by reduction; in comparison to non reducing gel, semi-quantitative evaluation about aggregate content possible
SDS Page non-reducing	Monomer and aggregate bands	band	
Pep Map	Disulfide bridging	no, weak, strong and very strong signal	Ability to detect peptides depends on the sensitivity of the measuring device
SEC Formulation	average molecular weight	kDa	For samples in a similar matrix as formulation buffer. RT of peak maximum is correlated to MW.
RPC NLS	NLS concentration	mg/ml	

Further details of the respective assays for the investigated mutants are summarized and discussed in the following Examples 5 to 12.

#### Example 5

##### Mass Balance after Solubilization and Refolding—Results RPC1 Titer Determination

Protein concentration prior and after solubilization and refolding of IB's was measured with the titer assay. As this assay measures all soluble protein present in the sample, mass

balance should yield 100%. Mass balance for solubilization was calculated using equ. 1.

$$\% Sol = \frac{mg_{RPC1} IB.SOL}{mg_{RPC1} IB.RES} \quad \text{equ. 1}$$

where  $mg_{RPC1} IB.SOL$  is the mass of protein in the solubilization solution of the IB's calculated from concentration measurement by RPC 1 method and volume of IB SOL solution.  $mg_{RPC1} IB.RES$  is the mass in the 20% IB suspension calculated from concentration measurement by RPC 1 method and volume of the solution after resuspension of the isolated IB's in DI.

Mass balance for refolding was calculated using equ. 2 and is expressed as % recovery. IB's solubilized with either 4% NLS, 8 M urea+/-5 mM DTT or 6M GuHCl+/-5 mM DTT were diluted and refolded as described in 3.3.1 and 3.3.2, respectively.

$$\% Ref = \frac{mg_{RPC1} Ref.END}{mg_{RPC1} IB.SOL} \quad \text{equ. 2}$$

where  $mg_{RPC1} Ref.END$  is the mass of protein according to concentration measurement with RP-HPLC found in the



## 21

refolding solution times volume of refolding solution.  $mg_{RPC1}$  IB.SOL is the mass of protein found in the IB solubilisate, % REF is the recovery after refolding.

Mass balance after solubilization with 4% NLS and subsequent refolding of all mutants as calculated by equations 1 and 2 are illustrated in FIG. 3. Raw data can be found in Tables 6 and 7.

Table 6 shows the recovery after solubilization with NLS of the IB\_RES suspension and recovery after refolding calculated from analytical method RPC I for all tested mutants. Also shown is the protein concentration in the IB-RES solution and protein concentration in the refolding solution determined by analytical method RPC I. Table 7 shows protein concentration determined by RPC I of IB\_RES, IB\_SOL and REF.END samples after solubilization with urea (SOL:urea) and solubilization with GuHCl (SOL:GuHCL). Refolding time was 96 hrs at 4° C. The dilution factor was 500 and 50 for IB\_RES and IB\_SOL, respectively to yield the REF.END solution.

TABLE 6

Mutant #	c [mg/ml] IB_RES	Recovery solubilization (%)	c [mg/ml] ref.end	Recovery refolding (%)
MYC 138	27.2	110	1.18	72
MYC 123wt	54.9	138.75	1.65	99.2
MYC 140	18.7	105.55	1.46	82.8
MYC 137	19.2	150.25	1.83	83.7
MYC 139	19.9	138.66	1.82	84.2
MYC 119	13.6	152.27	1.59	84.84
MYC 118	19.8	136.1	1.77	89.8
MYC 136	15.1	141.5	1.76	90.1
MYC 133	16.3	117.175	2.09	94.1
MYC 135	11	135.65	1.82	96.3
MYC 134	35.9	77.35	2.73	99.1
MYC 106	13.7	124.75	2.95	87.1
MYC 130	19.4	87	1.84	92.9

TABLE 7

Mutant #	c IB_RES	c IB_SOL	SOL: urea c REF.end	SOL: GuHCl c REF.end
MYC 118	19.8	2	0.091	0.075
MYC 119	13.6	3.46	0.07	0.056
MYC 130	19.4	2.94	0.044	0.026
MYC 133	16.3	1.34	0.023	0.0193
MYC 135	11	1.41	0.035	0.042

Mass balance of solubilization was exceeding 100% for 10 of the 12 investigated mutants. This could be due to the fact that the IB suspension was a crude sample type and eventually, the IB's were not completely dissolved when the sample was taken, leading to an inhomogeneous solution and thus underestimating total protein concentration. Data variability is high, with a relative standard deviation for 6 mutants analyzed twice ranging from 2.6% (Myc 138) to 42.9% (Myc 133). % Recovery after refolding was between 72% (Myc 138) and 99% (Myc 134). The expected recovery is 100% (similar to recovery after solubilization). Recoveries after refolding were all lower than 100% and scatter not as much as for recovery after solubilization. This indicates that estimation of protein concentration in IB.SOL and REF.end samples is more accurate than in IB.RES samples. However, calculation of recovery primarily serves as a control for solubilization and refolding experiments.

Refolding yields related to the solubilization solution IB.SOL and the IB suspension IB.RES when 8M urea or 6M GuHCl was used as solubilization agent are shown in FIG. 4.

## 22

The recovery varies from 44% to 230% reflecting the problems with measurement of protein concentration especially in IB.SOL and IB.RES samples, possibly due to insufficient homogenization prior to sampling.

Concentration in the REF.END samples after urea solubilization was comparable to concentration in REF.END after GuHCl solubilization (see Tables 6 and 7) though by an average factor of 1.2 higher. Dilution was thus consistent.

## Example 6

## Solubilization Time

Solubilization time with NLS was studied for all mutants. The time until the solution started to become clear and the time until no further clarification could be observed was recorded and is illustrated in FIG. 5.

In contrast to using 2% NLS, solubilization with Urea+/- DTT and GuHCl+/-DTT was 2-3 times faster.

A correlation between the number of Cysteines and time required for clarification to start was found. With the exception of mutant 134 (5 cys), mutants with 4 cysteine residues solubilized faster than mutants with 5 cysteine residues. FIG. 6 shows a variability chart where START [min] of clarification is plotted versus the 3 categories: alignment of heavy or light chain fragment at the N-terminus, number of linker elements and cysteine residues. With exception of Myc 134, indicated with 1 in FIG. 6, data points in category with 4 Cysteines scatter around earlier solubilization start times than compared with data points in the category with 5 cysteines.

A regression model ( $R^2=0.72$  when Myc 134 is excluded) predicted that start of solubilization would decrease from 20 min to 11.3 min for a Mycograb construct with 4 cysteines instead of 5 (model not shown).

## Example 7

## RPC 2—NLS Refolds

Mycograb REF.END samples solubilized and refolded according to Biomeva adapted process (described in Example 4) mutants were analyzed by RPC 2.

An overlay of REF.END samples from all investigated mutants including the wild type (MYC 123) is shown in FIG. 7 and FIG. 8. Mutant Myc 116 was screened earlier in lab DSP-DEV 1 and was included in the overlay for comparison reasons.

In FIG. 7, chromatograms of REF.END samples generated from IB's isolated at bench scale and in FIG. 8, chromatograms of REF.END samples generated from IB's isolated at larger scale in the pilot plant are shown.

Elution Profiles were Compared with Respect to:

1. Retention time peak 1, reflecting hydrophobicity
2. Shape of peak 1, reflecting presence of dimer and homogeneity of monomer species when the peak is sharp
3. Ratio area of monomer/dimer peak (peak 1) to aggregate/impurity peak (peak 2), reflecting aggregate/impurity content

Retention Time Peak 1, Reflecting Hydrophobicity

The retention time of the monomer/dimer peak for the tested mutants is listed in Table 8.



TABLE 8

Retention time [min] of peak 1 in RPC2 for the tested mutants and the molecule properties				
Mutant	t <sub>r</sub> , min]	linker	cystein	chain orientation
MYC 130	ave: 8.16 n = 3; RSD = 4.6%	3X	4	VH
MYC 106 origami	9.8	3X	4	VH
MYC 138	9.99	5X	4	VH
MYC 139	10.035	6X	4	VH
MYC 123_Wt	10.041	3X	5	VH
MYC 118	10.075	4X	5	VH
MYC 137	10.116	4X	4	VH
MYC 134	10.26	6X	5	VH
MYC 140	10.526	4X	4	VL
MYC 119	10.535	4X	5	VL
MYC 135	10.558	5X	5	VL
MYC 136	10.637	6X	4	VL
MYC 133	10.659	5X	5	VH

Retention time varies greatly with molecule construct. There is no trend of retention time (reflecting hydrophobicity) increasing with linker length, as would be expected. One linker element consists of four Glycines and one Serine residue. Glycine is hydrophobic in contrast to Serine, which is hydrophilic. However, the 4x higher Glycine content in the linker seems not to significantly increase the hydrophobicity as measured by retention time in RPC 2.

Retention time of Myc 130 is shorter than for the rest of the mutants. 10 amino acids were replaced by amino acids of more hydrophilic (5 serines) nature, thus decreasing the hydrophobicity of the molecule and consequently resulting in earlier retention time. Excluding this data point from statistical analysis results in a model showing significant difference in retention time when the orientation of the VL is N-terminal compared to an orientation when its C-terminal. Retention time increases by 0.41 min when the VL element is located N-terminal compared with when its located C terminal. FIG. 9 shows the scaled estimates and a prediction profiler of the model with number of cysteines, linker length and chain fragment orientation as factors and retention time as response.

Note that retention time of Myc 130 was excluded from the model. A plot of retention time versus linker length, shown in FIG. 10, demonstrates that retention time for this construct is lower compared to the rest of the mutants because of point mutations resulting in more hydrophilic nature, as mentioned above.

#### Shape of Peak 1

It is assumed that a sharp peak 1 with no or only little shoulders reflects the homogeneity of a monomeric Mycograb. Peak shape was assessed by overlays of the RPC 2 chromatograms of REF.End samples from all mutants and sharpest peaks were determined for the mutants Myc 137, Myc 138 and Myc 139. Peak 1 was sharper than the wild type Myc 123 and peaks 1 and 2 were almost base-line separated. This may be an indication that these constructs express the monomeric/dimeric protein with greater homogeneity than the wild type.

#### Ratio Area of Monomer/Dimer Peak

Impurity/aggregate content in relation to monomer/dimer was lowest for Myc 116 and MYC123 wt as shown in FIG. 7 (Myc 123 wt). However, analysis of these two samples was performed 3 months earlier by another laboratory and an increase of peak 2 was noticed over time. A chromatogram of

REF.End sample from Myc 123 that was prepared and analyzed in the same month as REF.End samples of the tested mutants is shown in FIG. 8. Comparison of the chromatogram of MYC 123 shown in FIG. 7 with that of shown in FIG. 8 leads to the conclusion that sample preparation and analytical method are not exactly reproducible.

The area ratio of monomer/dimer peak to aggregate peak was determined by normalizing peak 1 to the same peak maximum. The peak area of peak 2 after normalization was ranked according to increasing size using visual area estimation. The normalized overview is shown in FIG. 11.

The Following Ranking could be Established:

Myc 116, Myc 139, Myc 136<Myc 119, Myc 12, Myc140<Myc137, Myc 135, Myc138<Myc106<Myc130<Myc 134<Myc118<Myc133

RPC 2 chromatograms of REF.End samples generated from IBs of mutants Myc 106, 134, 136-139 were processed in the pilot plant and showed lower impurity/aggregate peaks (cf FIG. 8) than IB's of mutants Myc 118-135 isolated at bench scale.

#### Example 8

##### RPC 2 Urea/GuHCl Refolds

Mutants Myc 118, 119, 130 and Myc 133 were dissolved with 7,6M Urea+/-DTT and 5,6M GuHCl+/-DTT and refolding was initiated by dilution in refolding buffer.

All REF.End samples did not show the monomer/dimer peak (peak 1) in RPC 2. A huge peak 2, assumed to be aggregates and impurities is predominant. A representative RP HPLC chromatogram of a refold end sample from mutant Myc 119 is given in FIG. 12. The sample was prepared as described in Example 4.

The monomer was expected to elute at approximately 10.5 min. Peaks eluting earlier are not identified and were not observed in refolds with 0.5% NLS. The huge peak 2 indicates strong aggregation. Similar elution profiles were obtained for all REF.End samples after urea/GuHCl solubilization.

Similar elution profiles were obtained when the refold was done by 1:10 dilution with a buffer containing 20 mM Tris/Base, 0.5M L-arginine and 2 mM Cystin at pH 9.0. A representative chromatogram is shown in FIG. 13.

The strong aggregation tendency was confirmed by SDS-Page under non reducing conditions, a huge and intense HMW smear was detected for a REF.End sample, with no monomeric band visible after urea solubilization. This smear then disappeared when the sample was reduced and a monomeric Mycograb band appeared. In FIG. 14, SDS Page analysis of a reduced and non-reduced REF.End sample after urea solubilization is shown. Lanes 4-7 show REF.IM and REF.End sample of MYC 119 under non-reducing conditions at 2 different dilutions. Lanes 10-13 show the same sample under reducing conditions. The aggregate smear disappeared when the sample was reduced and the monomeric as well as the dimeric band became visible.

Urea and GuHCl were present in the refolding solution at low concentration (0.14M in case of a 1:50 dilution and 0.72M in case of a 1:10 dilution for urea; for GuHCl, it was 0.11M in case of a 1:50 dilution and 0.56M in case of a 1:10 dilution) cannot prevent the protein from aggregation. Using DTT does not seem to have a significant effect on aggregation as RP-HPLC chromatograms (RPC 2) with and without DTT looked comparable, as shown in FIG. 12.

In contrast to the REF.End sample, RPC 2 chromatogram of a IB.SOL sample dissolved with urea was comparable in



25

terms of peak shape with a IB.SOL sample dissolved in 2% NLS. FIG. 15 shows an overlay of HPLC chromatograms.

SDS-Page analysis of a non-reduced IB.SOL sample showed stronger HMW bands when the sample was dissolved with urea than in case of a IB.SOL sample dissolved in 2% NLS. This is shown in FIG. 14: in lane 3, the sample was solubilized with urea and in lane 8, the sample was solubilized with 2% NLS. It can be concluded that peak 2 in RP-HPLC does not give an indication about aggregate content since peak 2 of an chromatogram overlay is even smaller for an IB.SOL sample in urea than in NLS.

Subsequent refolding did not yield a monomeric peak but the protein completely aggregates.

#### Example 9

##### SDS-PAGE Reducing and Non-Reducing

Reducing and non-reducing SDS-Page was performed to determine impurities and aggregates content in REF.End samples. With reducing SDS-Page Mycograb species appeared as monomeric and dimeric band and host cell impurity content in the sample could be distinguished from aggregated species when compared to a non-reducing SDS-Page gel. Non-reducing SDS Page showed Mycograb monomers, dimers and aggregates. Comparing a non-reduced SDS-Page silver stain gel with a reducing SDS-Page analysis, the amount of aggregated species could be evaluated semi-quantitatively.

Reducing and non-reducing SDS-Page gels of REF.END samples of all tested mutants are shown in FIG. 16 and FIG. 17.

The gel in FIG. 16 on the left side shows a reducing SDS-Page of REF.End samples from mutants MYC 118, 119, 130, 133, 134, 135, 137. The band at 30 kDa is monomeric Mycograb and it is predominant in all samples. According to the migration of the monomeric band, Mycograb expressed in mutant MYC 134 seems to have higher molecular weight than the other mutants analyzed on the gel. The same but to a lesser extend was detected for MYC 135. According to Table 9, MYC 134 has the highest theoretical molecular weight among the mutants shown in FIG. 16, followed by MYC 135.

In the non reducing SDS-Page gel, aggregated species as well as the dimer are visible. In lanes 13 (MYC 134) and 15 (MYC 137), HMW bands are fainter than in the other lanes. This would indicate a lower content of aggregated species, however, also the bands for the monomer are more faint.

Double bands of different migration time and intensity in comparison with each other were observed for all mutants with exception of Myc 133 shown in FIG. 16. Identification of these bands was hardly possible, however it was assumed that it was Mycograb Monomer of native like structure.

FIG. 17 shows a reducing and non-reducing SDS Page of REF.End samples from mutants MYC 106, 136, 138, 139, 140 and the wild type, MYC 123. Differences in MW for the different constructs could be determined according to different migration of the monomeric band. The bands in lanes 5 and 7 appeared at a slightly lower MW than the bands in lanes 2,3,6 and 4 which was in agreement with the theoretical MW listed in Table 9.

The mass of protein applied to the gel was not consistent; monomeric bands varied in intensity because protein concen-

26

tration determination in the REF.End sample was not accurate enough. Thus semi-quantitative analysis of impurity content was not possible. However, the higher impurity content in REF.end sample of Myc 106 was obvious as the thickness of the monomeric band was comparable to one of Myc 140 but the intensity of the other bands was much higher.

SDS-Page analysis indicated that a REF.End sample of Myc 106 origami contained more HCP and product related impurities. However, this was not confirmed by RPC2 analytical method, where the area of peak 2 was in the same range as for the other mutants.

#### Example 10

##### SEC 0.5% NLS: Determination of Molecular Weight of Mycograb Species in the REF. END Sample

All REF.END samples prepared according to the adapted Biomeva process (see Example 4) were analyzed with SEC—HPLC in 0,5% NLS and the average molecular weight was determined. An overlay of the SEC chromatograms is shown in FIG. 18 and FIG. 19.

The average molecular weight ranged from 48.6 kDa to 65.8 kDa. The broadness of the peaks reflects the heterogeneity of species in the sample. Though approximately 80% of the product was monomeric in REF.End samples, dimers and higher MW species were present as well as non-product related impurities, resulting in a broad elution peak.

In FIG. 18, the elution profile of Myc 130 sticks out because of increased fronting compared with the other investigated samples. This might have been due to increased heterogeneity in the sample because of the construct's nature (more hydrophilic) or due to an accidentally different sample treatment.

Samples shown in FIG. 18 were prepared simultaneously and stored at 4° C. for 5 days prior to analysis. Samples shown in FIG. 19 were prepared simultaneously and stored at 4° C. over night days prior to analysis. Samples seemed to be stable at 4° C. as MW of the constructs were in a similar range.

Fronting of Myc 130 may have been due to higher amount of aggregated species compared with the other investigated samples. However, peak 2 in the corresponding RPC 2 chromatogram was not outstandingly large but it has been observed that there is only sometimes a correlation between increased MW determined by SEC 0.5% NLS and large peak 2 peak area, determined with RPC2.

Additionally, SDS-page of Myc 130 did not indicate a higher impurity content and increased heterogeneity of the sample. Other factors leading to fronting in SEC such as column overloading and increased temperature during analysis can be excluded as all samples were analyzed on the same day.

There was a very early retention time for Myc 130 in RPC2.

It was assumed that the average MW in a REF.End sample was increasing for an increasing amount of dimers, aggregates and impurities. The calculated MW of a monomeric Mycograb expressed in the different mutants was between 26 and 27 kDa because of the different linker length and other mutations. A table listing theoretical MW-calculated from the amino acids-, MW of the REF.End sample determined by SEC, # of amino acids, linker length and number of cysteines is given in Table 9.



TABLE 9

SEC-HPLC 0.5% NLS results of REF.End samples from all tested mutants. The mutants are ranked according to their theoretical molecular weight.

MUTANT	MW theory	SEC	# aa	Linker length	Number of cysteines
MYC 130	26.1	65.8	246	3X	4
MYC 118	26.4	48.6	251	4X	5
MYC 137	26.466	47.1	251	4X	4
MYC 119	26.5	49.9	252	4X	5
MYC 140	26.55	49.3	252	4X	4
MYC 133	26.7	57.9	256	5X	5
MYC 138	26.78	51.0	256	5X	4
MYC 135	26.8	52.2	257	5X	5
MYC 136	27.018	64.6	261	6X	5
MYC 134	27.062	62.6	261	6X	5
MYC 139	27.09	64.7	261	6X	4
MYC 123Wt	27.32	63.5	256	3X	5
MYC 106 origami	27.38	61.5	256	3X	4

Theoretical MW was plotted versus MW determined by SEC and a linear relationship with a correlation coefficient of 0.77 was found when the data point for Myc 130 was excluded.

Mutants Myc 106, Myc 138 and Myc 135, represented by dots to the right of the lower dashed line in FIG. 20, had a

factor of 5 from the REF.End solution with ultra/diafiltration using a stir cell. The total buffer volume used during diafiltration divided by the retentate volume is the diafactor and was 2.5.

5 The rationale of this experiment was to investigate aggregation tendency of the mutants when the dissolving agent NLS is lowered to a concentration at which aggregation cannot be prevented anymore.

10 It was assumed that formation of aggregates can be assessed with SEC-HPLC formulation. The elution buffer contained 0.5M urea buffer but no NLS to suppress aggregation.

15 Increase in molecular weight was used as a measure of tendency to aggregate and allows the mutants to be compared.

Mutants Myc 137, Myc 106, Myc 119 and the wild type Myc 123 were selected for a first set of experiments. Table 10 shows the molecular weight (MW) in kDa determined by SEC—HPLC running in formulation buffer and concentration of NLS (%) determined by RP-HPLC for REF.End samples from mutants MYC 119, 137, 106 and MYC 123 before and after UFDF. The NLS reduction factor was calculated from NLS concentration in the sample prior to UFDF (#2) divided by the concentration of NLS after UFDF (#3). The % increase MW based on SEC HPLC 0,5% NLS was calculated from the MW of the .REF.END sample (#1) and the MW after UFDF (#3) for the respective Mutant.

TABLE 10

Sample no.	Sample code	MYC 123		MYC 119		MYC 106 origami		MYC 137	
		MW [kDa]	c NLS %	MW [kDa]	c NLS %	MW [kDa]	c NLS %	MW [kDa]	c NLS %
#1	REF. END*	63.5[**]	n.d	49.3[**]	n.d	61.5 [kDa][**]	n.d	47.1[**]	n.d
#2	Prior to UFDF	214	0.52	359	0.58	202	0.607	212	0.57
#3	After YFDF	178	0.08	245	0.171	184	0.132	194	0.114
	NLS reduction factor		6.5		3.4		4.6		5
	% increase MW based on*	180%		397%		199%		312%	

\*The molecular weight was determined with an analytical SEC HPLC method containing 0.5% NLS in the running buffer (SEC HPLC 0.5% NLS).  
[\*\*]data from Table 9.

lower average MW than the wild type. Mutants Myc 133, 136 and 139, represented by dots to the left of the higher dashed line had a higher average MW than the wild type. However, assay variability has to be taken into account. Additionally, from FIG. 19 it can be seen that the mass of injected protein was not always the same as peak area for some of the samples. Formation of covalent aggregates should be decreased for mutants with 4 cysteines as compared with Mycograb with 5 cysteines because no free cysteine in mutants with 4 cysteines is available after formation of intermolecular SS bridges. Intermolecular covalent aggregates are formed during refolding even with a mutant with only 4 cysteines but it would be likely that the amount is lower than for a mutant with 5 cysteines.

#### Example 11

##### SEC Formulation: NLS removal by UF/DF from Refolding Solution to Measure Aggregation Tendency

In order to evaluate aggregation tendency of Mycograb mutants, the NLS concentration was lowered by an average

45 The apparent high molecular weight determined by SEC HPLC (running with formulation buffer) of the sample prior to UFDF was due to aggregation of protein during analysis.

50 The sample prior to UFDF still contained 0.5% NLS. As the sample migrated through the column, NLS was more strongly retarded than the protein and consequently aggregation occurred. Therefore this analytical method was not suited to determine molecular weight of samples containing NLS.

55 In order to determine molecular weight of Mycograb in the REF.End sample, SEC HPLC with 0.5% NLS in the running buffer was used. The increase in MW after removal of NLS in the REF.End sample by UFDF was calculated as described above in relation to Table 10. Values are shown in row 6 of Table 10. MYC 123 showed the smallest increase in MW whereas MYC 119 had the strongest increase, 400%.

60 MYC 123 has a lower aggregation tendency than MYC 119 based on these data. However, it has to be considered that the analytical SEC HPLC may have an influence on the protein structure and on the formation of aggregates. Moreover, increase of MW is calculated from data obtained from two different analytical methods and it cannot be assessed if the MW of a sample is similar when it is determined with the two different methods.



In Table 11, the mutants are ranked according to increase in MW after NLS removal together with the mutations. It has to be noted that the two mutants with a 3× linker element have significantly lower % of MW increase compared with mutants with a 4× linker element.

TABLE 11

Increase of molecular weight after removal of NLS by UFDF for the 4 investigated mutants.					
MUTANT	% molecular weight increase	HIS tag	Linker length	VH-VL alignment	cysteins
MYC 123 Wt	180	YES	3X	VH N-terminal	5
MYC 106 origami	199	YES	3X	VH N-terminal	4
MYC 137	312	NO	4X	VH N-terminal	4
MYC 119	397	NO	4X	VL N-terminal	5

FIG. 21 shows an overlay of the SEC HPLC chromatograms obtained from the sample prior to UFDF and after each volume reconstitution. The shape of the elution peaks did not significantly change with reduction of NLS concentration. Consequently, the MW of the sample also remained constant with reduction of NLS. This might be an indication that there is a limit in the concentration of surfactant below which aggregation is initiated but does not proceed further. However, the impact of the analytical method on the MW of the sample is not known and may be the reason why all samples have similar MW.

The NLS concentration was reduced on average (n=5) to a concentration of 0.124% after 5 volume reconstitutions, corresponding to a diavolume of 2.5. Theoretically, for a retention R=0 of NLS, the calculated remaining NLS concentration should be 0.020%. Equation 3 was used for calculation of the theoretical remaining NLS concentration:

$$C_{retentat} = C_{feed} \times (e^{(R-1) \times [INVCF+N]}) \quad \text{equ. 3}$$

where  $C_{retentat}$  is the concentration of NLS in the retentate,  $C_{feed}$  is the concentration of NLS in the feed solution. R is the retention, the fraction of solute that is retained by the membrane. VCF is the volume concentration factor and N is the diavolume which is the total buffer volume introduced to the operation during diafiltration divided by the retentate volume.

The discrepancy between the theoretical and the measured concentration of NLS in the retentate is an indication for

retention of NLS by the membrane greater than 0. This might be due to interaction between NLS and the protein, membrane and/or other components. The ability to deform can also cause unwanted retention.

## Example 12

## Pep-Map Analysis

REF.End samples of all mutants were analyzed for disulfide bridging with peptide map. Prior to analysis, the sample was alkylated with iodoacetamide, digested with trypsin and subjected to LC-MS. UV peaks of the single peptides were identified with mass spectrometry. The peptides with free SH groups, correctly and incorrectly formed S—S bonds as well as dimeric peptides were, whenever possible, semi-quantitatively determined.

A correctly folded construct with 5 cysteines forms an S—S bond between Cys 23 and Cys 97 which corresponds to T3 and T9 respectively. The bond T3-T9 is located in the light chain. The other disulfide bond is on the heavy chain between Cys 159 and Cys 224, corresponding to T12 and T17. The 5<sup>th</sup> cysteine is located at Cys28 and corresponds to the T4 peptide.

A construct with 4 cysteines always lacks the Cys 28 residue, the correct S—S bridges are similar as for a construct with 5 cysteines.

Mutants 118, 119, 130, 135, 133, 134, 137 and C28Y+HIS (106) as well as C28Y-HIS (108) were analyzed in lab AL1. Mutants 106 origami, 136, 138, 139, 140 and the wild type 123 were analyzed in analytical lab AL2 with a different device. The sensitivity of the mass spectrometer in AL1 is higher than that in AL2 and therefore, a semi-quantitative analysis of mutants analyzed in AL2 could not be obtained. However, it was possible to determine if correctly formed SS bridges are present.

A summary of the obtained data is given in Table 12. The results are compiled in 3 categories: free SH, bridged cysteines and dimeric cysteines. Free cysteines indicate a SH group that did not form a disulfide bond. Bridged cysteines are intramolecular disulfide bonds and dimeric cysteines represent intermolecular disulfides. W indicates that a weak signal for the respective peptide was detected and X represents peptides giving strong signals. Mutants analyzed in AL 2 are labeled with \*.

TABLE 12

		Pep Map analysis of all tested mutants													
		Mutants with 5 cysteins							Mutants with 4 cysteins						
		Myc 118	Myc 119	Myc 133	Myc 134	Myc 135	Myc 123*	Myc 106* origami	Myc 130	Myc 137	Myc 138*	Myc 139*	Myc 140*	Myc (C28Y + HIS)	Myc (C28Y - HIS)
Free cysteins bridged	Free SH at T4	w	w	w				no T4!							
	All other free SH correct disulfides	w	w	w	w	w	X								
cysteins	T3-T9	w	w	w		w		X	X					X	X
	T12-T17	X	X	X					X					X	X
	incorrect disulfides														
	all other combinations	X	X	X	X	X	X	X	X	X	X	w	X	X	X



TABLE 12-continued

		Pep Map analysis of all tested mutants													
		Mutants with 5 cysteins						Mutants with 4 cysteins							
		Myc 118	Myc 119	Myc 133	Myc 134	Myc 135	Myc 123*	Myc 106* origami	Myc 130	Myc 137	Myc 138*	Myc 139*	Myc 140*	Myc 106 (C28Y + HIS)	Myc 108 (C28Y - HIS)
Dimers	T9-T9 other dimers	X		w	w		w		X	w				w	w

A 'correctly' folded Mycograb with 5 cysteines should give a significant signal for free SH at the T4 peptide and no signal corresponding to other free SH groups. Additionally, a strong signal for the correct disulfides T3-T9 and T12-T17 is expected and incorrect SS bonds should not be present. Lastly, no intermolecular SS bonds should be present.

A 'correctly' folded Mycograb with 4 cysteines should not have any free SH groups. Only the correct S—S bonds T3-T9 and T12-T17 should be detected. Additionally, no intermolecular SS bonds should be present.

Table 12 shows that neither the wild type nor any of the mutants gave strong signals for the correct S—S bonds only. It has to be considered that the REF.End sample consists of a population of differently folded and covalently aggregated species, so that a mixture of all possible combinations of disulfide bonds and free SH groups is present. However, a promising mutant should at least show significant signals for both of the correct S—S bridges which is the case for MYC 137 and the mutants C28Y+HIS and C28Y-HIS.

In 5 cases, only incorrect S—S bonds were found, where no, or only a weak, signal was obtained for the correct disulfide bonds.

Signals for MYC 123, MYC 138, MYC 139 and MYC 140 were extremely weak and reanalysis of the samples did not yield higher signals. Though Mycograb specific peptides were found, the cysteine containing peptides gave no or only a weak signal. This might be due to ineffective digestion of the respective portion of the protein with trypsin because of structurally blocked cleaving sites. It was also noted that mutants with increased linker length (5 and 6× instead of 3×) were more difficult to digest and consequently signals for the late eluting peptides could not or could only hardly be detected.

Interestingly, covalent disulfides were, with one exception, only formed between the two T9 peptides, corresponding to Cys 97 residues.

Mutants Myc 118, 119, 130, 133, 137 and the mutants C28Y+HIS and C28Y-HIS gave stronger signals for correct S—S bonds than the wild type. However, it has to be considered that Myc 123 was analyzed with a different mass spectrometer of lower sensitivity and hence signal intensities cannot be compared. Signals from peptides of Myc 123 can be compared with signals from mutants 106 origami, 136, 138, 139 and 140. For none of these constructs, correct disulfide bridges were obtained. Only signals for incorrect disulfides were found.

Pep Map results for Myc 137, Myc C28Y+HIS and Myc C28Y-HIS were most promising with significant signals for both correct disulfide bridges. Mutants Myc 118, Myc 119 and Myc 133 also showed a certain amount of native like disulfide bridging, however, the signal for T12-T17 was weak.

Mutant Myc 130 showed strong signals for the T12-T17 SS bond, but the second correct disulfide was not found.

## CONCLUSIONS

### Correlations of Analytical Results

The best recoveries after refolding were obtained with the MYC 123 (wt) and MYC 134, as determined by the titer assay with Poros column (RPC 1).

The solubilization of IBs with chaotropic agents was faster than solubilization with NLS. RPC 2 chromatograms of IBs solubilized with urea or NLS were comparable. However, SDS Page indicated a stronger dissolving power of NLS as the aggregate smear was reduced compared with IBs solubilized with urea, see FIG. 14.

Refolding after solubilization with chaotropic agents by dilution and use of different additives such as Cysteine, L-Arginine, 1% NLS and low concentration of urea/GuHCl did not show a monomeric peak in RPC 2, see FIG. 12 and FIG. 13. The protein completely aggregated which was confirmed by SDS Page, non reducing and the RPC 2 chromatogram showed a huge peak 2.

The determination of MW with SEC HPLC 0.5% NLS correlated with an  $R^2$  of 0.77 with the theoretically calculated MW when 1 outlier was excluded. The resolving power of SDS PAGE was not sufficient to detect all subtle differences in MW, but a migration time difference was seen between two mutants of a MW differing by 0.6 kDa in theory and 14 kDa as measured with SEC HPLC (MYC 134 and MYC 118, respectively).

RPC 2 chromatography was able to confirm decreased hydrophobicity of a mutant where 10 hydrophobic amino acids were replaced by more hydrophilic ones (MYC 130). The linker element did not have easy access to binding sites of the stationary phase and did not therefore have influence on retention behavior. It was also observed that Pep Map analysis for constructs with increased linker length gave weaker signals for the peptides of interest compared with constructs with shorter linker. It appeared that the linker element was not easily accessible for the digesting enzyme.

RPC2 chromatograms for MYC 137, 138 and 139 showed the sharpest peak which is attributed to a Mycograb Monomer compared with the other tested mutants, indicating increased homogeneity of the sample.

Pep Map analysis showed that almost no free SH group was present in REF.End samples for mutants with 4 Cysteines. This indicates an almost complete formation of disulfide bridges (incorrect and correct ones) as well as formation of covalent aggregates. For mutants with 5 cysteines, weak signals were obtained for various free SH groups but only mutants Myc 118, Myc 119 and Myc 133 had a free SH group



at T4, the location of the 5<sup>th</sup> cysteine which should remain reduced in the 'native.' monomer. This is an indication that the SH group on the T4 peptide preferably forms SS bonds because all mutants with 5 cysteines gave signals for free SH groups but only in 3 of them a free SH group at T4 was detected.

MW determined with SEC HPLC is very dependent on the buffer matrix in the sample. A couple of SEC HPLC methods had to be established with a running buffer similar to the buffer of the sample. The matrix dependency of MW determination makes comparison of MW across process steps difficult (Table 10).

The UFDF experiment showed that NLS is to some extent retained in the sample solution and cannot efficiently be removed.

The results obtained with Pep Map of Mutants MYC C28Y+HIS, C28Y-HIS and MYC 137 were particularly promising. The results indicate that a mutant with a HIS tag

and only 4 cysteines is particularly preferred. The HIS tag is required for purification with IMAC, a purification step of high efficiency. A construct with only 4 cysteines is more likely to form correct disulfides and covalent aggregates.

#### Effects of Mutations

The most beneficial effect of the mutations can be attributed to the removal of the 5<sup>th</sup> cysteine. The number of correct disulfide bonds was increased compared with constructs with 5 cysteines. Additionally, solubility of the IBs was enhanced compared with constructs with 5 cysteines.

Exchanging the orientation of the heavy and light chain fragment had a minor effect on retention time in RPC 2 where the retention time decreased when the VL element was C terminal compared with an N-terminal orientation.

The tendency of the peptides to aggregate after NLS removal may be increased with the number of linker elements.

---

#### SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 71

<210> SEQ ID NO 1

<211> LENGTH: 771

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(771)

<400> SEQUENCE: 1

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg	48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct	96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser	
20 25 30	
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa	144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg	192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc	240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac	288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser	
130 135 140	
ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc	480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys	







-continued

Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
225 230 235 240

Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His  
245 250 255

<210> SEQ ID NO 3  
<211> LENGTH: 774  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
<220> FEATURE:  
<221> NAME/KEY: CDS  
<222> LOCATION: (1)..(774)

<400> SEQUENCE: 3

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg 48  
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
1 5 10 15

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct 96  
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser  
20 25 30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa 144  
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
35 40 45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg 192  
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
50 55 60

agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc 240  
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
65 70 75 80

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac 288  
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
85 90 95

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg 336  
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
100 105 110

ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt 384  
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
115 120 125

ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc 432  
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser  
130 135 140

ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc 480  
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys  
145 150 155 160

cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca 528  
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala  
165 170 175

ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa 576  
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
180 185 190

acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc 624  
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
195 200 205

acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac 672  
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
210 215 220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa 720  
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
225 230 235 240



-continued

---

```

gtg gac atc aaa cgc gcg gcc gca ctc gag cac cac cac cac cac cac 768
Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His
                245                250                255

```

```

taa taa 774

```

```

<210> SEQ ID NO 4
<211> LENGTH: 256
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 4

```

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1                5                10                15

```

```

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser
                20                25                30

```

```

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
                35                40                45

```

```

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
50                55                60

```

```

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65                70                75                80

```

```

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
                85                90                95

```

```

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
100                105                110

```

```

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115                120                125

```

```

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
130                135                140

```

```

Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys
145                150                155                160

```

```

Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala
165                170                175

```

```

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
180                185                190

```

```

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
195                200                205

```

```

Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
210                215                220

```

```

Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
225                230                235                240

```

```

Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His
245                250                255

```

```

<210> SEQ ID NO 5
<211> LENGTH: 756
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(756)

```

```

<400> SEQUENCE: 5

```

```

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg 48

```



-continued

Met	Ala	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	
1				5					10					15		
ggt	gaa	tct	ctg	cgt	atc	tct	tgc	aaa	ggt	tct	ggt	tgc	atc	atc	tct	96
Gly	Glu	Ser	Leu	Arg	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Cys	Ile	Ile	Ser	
			20					25					30			
tct	tac	tgg	atc	agc	tgg	ggt	cgt	cag	atg	ccg	ggc	aag	ggc	ctg	gaa	144
Ser	Tyr	Trp	Ile	Ser	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	
		35					40					45				
tgg	atg	ggt	aaa	att	gat	ccg	ggc	gac	agc	tat	att	aac	tac	agc	ccg	192
Trp	Met	Gly	Lys	Ile	Asp	Pro	Gly	Asp	Ser	Tyr	Ile	Asn	Tyr	Ser	Pro	
	50					55					60					
agc	ttt	cag	ggc	cat	ggt	acc	atc	agc	gcc	gat	aaa	agc	att	aac	acc	240
Ser	Phe	Gln	Gly	His	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Asn	Thr	
65					70				75						80	
gct	tac	ctg	caa	tgg	aac	agc	ctg	aaa	gcg	agc	gac	acc	gcg	atg	tac	288
Ala	Tyr	Leu	Gln	Trp	Asn	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	
			85					90					95			
tac	tgt	gcc	cgt	ggc	ggt	cgt	gac	ttc	ggt	gat	agc	ttc	gat	tac	tgg	336
Tyr	Cys	Ala	Arg	Gly	Gly	Arg	Asp	Phe	Gly	Asp	Ser	Phe	Asp	Tyr	Trp	
			100					105					110			
ggt	cag	ggc	acc	ctg	gtg	acc	gtg	agc	agc	ggt	ggt	ggc	ggc	agc	ggt	384
Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly	
		115					120					125				
ggt	ggc	ggc	agc	ggc	ggc	ggc	ggc	agc	gat	ggt	gtg	atg	acc	cag	agc	432
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Val	Val	Met	Thr	Gln	Ser	
	130					135					140					
ccg	agc	ttc	ctg	agc	gcg	ttc	ggt	gac	cgt	atc	acc	att	acc	tgc		480
Pro	Ser	Phe	Leu	Ser	Ala	Phe	Val	Gly	Asp	Arg	Ile	Thr	Ile	Thr	Cys	
145					150				155						160	
cgc	gcc	agc	agc	ggc	atc	agc	cgc	tat	ctg	gcg	tgg	tat	cag	caa	gca	528
Arg	Ala	Ser	Ser	Gly	Ile	Ser	Arg	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Ala	
				165					170					175		
ccg	ggt	aaa	gca	ccg	aaa	ctg	ctg	atc	tat	gct	gca	agc	acc	ctg	caa	576
Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Thr	Leu	Gln	
			180					185					190			
acc	ggc	ggt	ccg	agc	cgt	ttt	agc	ggt	agc	ggc	agc	ggc	acc	gag	ttc	624
Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe	
		195					200					205				
acc	ctg	acc	atc	aac	agc	ctg	caa	ccg	gag	gat	ttt	gcc	acc	tat	tac	672
Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	
		210				215					220					
tgc	caa	cac	ctg	aat	agc	tat	ccg	ctg	acc	ttc	ggt	ggc	ggc	acc	aaa	720
Cys	Gln	His	Leu	Asn	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys	
225					230				235						240	
gtg	gac	atc	aaa	cgc	gcg	gcc	gca	ctg	gaa	taa	taa					756
Val	Asp	Ile	Lys	Arg	Ala	Ala	Ala	Leu	Glu							
				245					250							

<210> SEQ ID NO 6  
 <211> LENGTH: 250  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 6

Met	Ala	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	
1				5					10					15		
Gly	Glu	Ser	Leu	Arg	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Cys	Ile	Ile	Ser	
			20					25					30			



-continued

---

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser  
 130 135 140

Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys  
 145 150 155 160

Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala  
 165 170 175

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
 180 185 190

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
 195 200 205

Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
 210 215 220

Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
 225 230 235 240

Val Asp Ile Lys Arg Ala Ala Ala Leu Glu  
 245 250

<210> SEQ ID NO 7  
 <211> LENGTH: 756  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(756)  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (85)..(87)  
 <223> OTHER INFORMATION: A codon encoding an amino acid other than  
 cysteine

<400> SEQUENCE: 7

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg 48  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt nnn atc atc tct 96  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser  
 20 25 30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa 144  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg 192  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60

agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc 240  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80



-continued

```

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac      288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
                        85                      90                      95

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg      336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
                        100                      105                      110

ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt      384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
                        115                      120                      125

ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc      432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
                        130                      135                      140

ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc      480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys
145                      150                      155                      160

cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca      528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala
                        165                      170                      175

ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa      576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
                        180                      185                      190

acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc      624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
                        195                      200                      205

acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac      672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
                        210                      215                      220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa      720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
225                      230                      235                      240

gtg gac atc aaa cgc gcg gcc gca ctg gaa taa taa                        756
Val Asp Ile Lys Arg Ala Ala Ala Leu Glu
                        245                      250

```

&lt;210&gt; SEQ ID NO 8

&lt;211&gt; LENGTH: 250

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;222&gt; LOCATION: (29)..(29)

<223> OTHER INFORMATION: The 'Xaa' at location 29 stands for Lys, Asn, Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro, Leu, Tyr, Trp, Cys, or Phe.

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 8

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1                      5                      10                      15

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser
                20                      25                      30

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
                35                      40                      45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
50                      55                      60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65                      70                      75                      80

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
                85                      90                      95

```



-continued

---

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
                   100                  105                  110  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
                   115                  120                  125  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser  
           130                  135                  140  
 Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys  
   145                  150                  155                  160  
 Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala  
                   165                  170                  175  
 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
           180                  185                  190  
 Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
           195                  200                  205  
 Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
   210                  215                  220  
 Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
   225                  230                  235                  240  
 Val Asp Ile Lys Arg Ala Ala Ala Leu Glu  
                   245                  250

<210> SEQ ID NO 9  
 <211> LENGTH: 774  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(774)  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (85)..(87)  
 <223> OTHER INFORMATION: A codon encoding an amino acid other than  
                   cysteine

<400> SEQUENCE: 9

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg           48  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
   1                  5                  10                  15  
 ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt nnn atc atc tct           96  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser  
           20                  25                  30  
 tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa           144  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
           35                  40                  45  
 tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg           192  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
   50                  55                  60  
 agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc           240  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
   65                  70                  75                  80  
 gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac           288  
 Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
           85                  90                  95  
 tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg           336  
 Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
           100                  105                  110  
 ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt           384  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
           115                  120                  125



-continued

---

```

ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc 432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
   130                135                140

ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc 480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys
 145                150                155                160

cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca 528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala
   165                170                175

ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa 576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
   180                185                190

acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc 624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
   195                200                205

acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac 672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
   210                215                220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa 720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
 225                230                235                240

gtg gac atc aaa cgc gcg gcc gca ctc gag cac cac cac cac cac cac 768
Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His
   245                250                255

taa taa 774

```

```

<210> SEQ ID NO 10
<211> LENGTH: 256
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(29)
<223> OTHER INFORMATION: The 'Xaa' at location 29 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 10

```

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
 1                5                10                15

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser
   20                25                30

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
 35                40                45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
 50                55                60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
 65                70                75                80

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
   85                90                95

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
 100                105                110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
 115                120                125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
 130                135                140

Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys

```

-continued

145	150	155	160
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	165	170	175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	180	185	190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe	195	200	205
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr	210	215	220
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys	225	230	235
Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His	245	250	255

<210> SEQ ID NO 11  
 <211> LENGTH: 744  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(744)

<400> SEQUENCE: 11

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg	48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	1 5 10 15
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct	96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser	20 25 30
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa	144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	35 40 45
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg	192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	50 55 60
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc	240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	65 70 75 80
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac	288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	85 90 95
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	100 105 110
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	115 120 125
ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser	130 135 140
ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc	480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys	145 150 155 160
cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca	528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	165 170 175
ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa	576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	



-continued

180	185	190	
acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc			624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe			
195	200	205	
acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac			672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr			
210	215	220	
tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa			720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys			
225	230	235	240
gtg gac atc aaa cgc gcg taa taa			744
Val Asp Ile Lys Arg Ala			
245			

<210> SEQ ID NO 12  
 <211> LENGTH: 246  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 12

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro																			
1				5				10							15				
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser																			
20								25							30				
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu																			
35								40							45				
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro																			
50								55							60				
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr																			
65								70							75				80
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr																			
85															90				95
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp																			
100															105				110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly																			
115															120				125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser																			
130															135				140
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys																			
145															150				155
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala																			
165															170				175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln																			
180															185				190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe																			
195															200				205
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr																			
210															215				220
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys																			
225															230				235
Val Asp Ile Lys Arg Ala																			
245																			

<210> SEQ ID NO 13  
 <211> LENGTH: 744

-continued

---

```

<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(744)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (85)..(87)
<223> OTHER INFORMATION: A codon encoding an amino acid other than
cysteine

<400> SEQUENCE: 13

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg      48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1          5          10          15

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt nnn atc atc tct      96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser
          20          25          30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa      144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
          35          40          45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg      192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
          50          55          60

agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc      240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65          70          75          80

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac      288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
          85          90          95

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg      336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
          100          105          110

ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt      384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
          115          120          125

ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc      432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
          130          135          140

ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc      480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys
145          150          155          160

cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca      528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala
          165          170          175

ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa      576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
          180          185          190

acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc      624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
          195          200          205

acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac      672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
          210          215          220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa      720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
225          230          235          240

gtg gac atc aaa cgc gcg taa taa      744
Val Asp Ile Lys Arg Ala
          245

```



-continued

<210> SEQ ID NO 14  
 <211> LENGTH: 246  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (29)..(29)  
 <223> OTHER INFORMATION: The 'Xaa' at location 29 stands for Lys, Asn,  
 Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,  
 Leu, Tyr, Trp, Cys, or Phe.  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 14

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser  
 20 25 30  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95  
 Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser  
 130 135 140  
 Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys  
 145 150 155 160  
 Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala  
 165 170 175  
 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
 180 185 190  
 Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
 195 200 205  
 Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
 210 215 220  
 Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
 225 230 235 240  
 Val Asp Ile Lys Arg Ala  
 245

<210> SEQ ID NO 15  
 <211> LENGTH: 744  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(744)

<400> SEQUENCE: 15

atg gcg gaa gtg cag ctg gtt gaa tct ggt gct gaa gtt aaa aaa ccg  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro

-continued

1	5	10	15	
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct				96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser	20	25	30	
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa				144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	35	40	45	
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg				192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	50	55	60	
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc				240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	65	70	75	80
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac				288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	85	90	95	
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg				336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	100	105	110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt				384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	115	120	125	
ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc				432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser	130	135	140	
ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc				480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys	145	150	155	160
cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca				528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	165	170	175	
ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa				576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	180	185	190	
acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc				624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe	195	200	205	
acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac				672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr	210	215	220	
tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa				720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys	225	230	235	240
gtg gac atc aaa cgc gcg taa taa				744
Val Asp Ile Lys Arg Ala	245			

&lt;210&gt; SEQ ID NO 16

&lt;211&gt; LENGTH: 246

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 16

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	1	5	10	15
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser	20	25	30	
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu				





-continued

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac	288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser	
130 135 140	
ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc	480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys	
145 150 155 160	
cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca	528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	
165 170 175	
ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa	576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	
180 185 190	
acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc	624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe	
195 200 205	
acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac	672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr	
210 215 220	
tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa	720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys	
225 230 235 240	
gtg gac atc aaa cgc gcg taa taa	744
Val Asp Ile Lys Arg Ala	
245	

&lt;210&gt; SEQ ID NO 18

&lt;211&gt; LENGTH: 246

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;222&gt; LOCATION: (29)..(29)

&lt;223&gt; OTHER INFORMATION: The 'Xaa' at location 29 stands for Lys, Asn, Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro, Leu, Tyr, Trp, Cys, or Phe.

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 18

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser	
20 25 30	
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	



-continued

100				105				110							
Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly
		115					120					125			
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Val	Val	Met	Thr	Gln	Ser
	130					135						140			
Pro	Ser	Phe	Leu	Ser	Ala	Phe	Val	Gly	Asp	Arg	Ile	Thr	Ile	Thr	Cys
145					150					155					160
Arg	Ala	Ser	Ser	Gly	Ile	Ser	Arg	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Ala
				165					170					175	
Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Thr	Leu	Gln
			180					185					190		
Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe
		195					200						205		
Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr
	210					215					220				
Cys	Gln	His	Leu	Asn	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys
225					230					235					240
Val	Asp	Ile	Lys	Arg	Ala										
				245											

&lt;210&gt; SEQ ID NO 19

&lt;211&gt; LENGTH: 774

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Polynucleotide encoding scFv polypeptide

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(774)

&lt;400&gt; SEQUENCE: 19

atg gcg gaa gtg cag ctg gtt gaa tct ggt gct gaa gtt aaa aaa ccg	48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct	96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser	
20 25 30	
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa	144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg	192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc	240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac	288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser	
130 135 140	
ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc	480

-continued

Pro	Ser	Phe	Leu	Ser	Ala	Phe	Val	Gly	Asp	Arg	Ile	Thr	Ile	Thr	Cys		
145					150					155					160		
cgc	gcc	agc	agc	ggc	atc	agc	cgc	tat	ctg	gcg	tgg	tat	cag	caa	gca		528
Arg	Ala	Ser	Ser	Gly	Ile	Ser	Arg	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Ala		
				165					170					175			
ccg	ggt	aaa	gca	ccg	aaa	ctg	ctg	atc	tat	gct	gca	agc	acc	ctg	caa		576
Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Thr	Leu	Gln		
				180				185					190				
acc	ggc	ggt	ccg	agc	cgt	ttt	agc	ggt	agc	ggc	agc	ggc	acc	gag	ttc		624
Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe		
		195				200						205					
acc	ctg	acc	atc	aac	agc	ctg	caa	ccg	gag	gat	ttt	gcc	acc	tat	tac		672
Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr		
	210					215				220							
tgc	caa	cac	ctg	aat	agc	tat	ccg	ctg	acc	ttc	ggt	ggc	ggc	acc	aaa		720
Cys	Gln	His	Leu	Asn	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys		
225				230						235					240		
gtg	gac	atc	aaa	cgc	gcg	gcc	gca	ctc	gag	cac	cac	cac	cac	cac	cac		768
Val	Asp	Ile	Lys	Arg	Ala	Ala	Ala	Leu	Glu	His	His	His	His	His	His		
				245					250					255			
taa	taa																774

<210> SEQ ID NO 20  
 <211> LENGTH: 256  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 20

Met	Ala	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro		
1				5					10					15			
Gly	Glu	Ser	Leu	Arg	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Cys	Ile	Ile	Ser		
			20					25					30				
Ser	Tyr	Trp	Ile	Ser	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu		
		35				40						45					
Trp	Met	Gly	Lys	Ile	Asp	Pro	Gly	Asp	Ser	Tyr	Ile	Asn	Tyr	Ser	Pro		
	50				55						60						
Ser	Phe	Gln	Gly	His	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Asn	Thr		
	65				70					75					80		
Ala	Tyr	Leu	Gln	Trp	Asn	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr		
			85						90					95			
Tyr	Cys	Ala	Arg	Gly	Gly	Arg	Asp	Phe	Gly	Asp	Ser	Phe	Asp	Tyr	Trp		
		100						105					110				
Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly		
		115					120						125				
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Val	Val	Met	Thr	Gln	Ser		
	130					135					140						
Pro	Ser	Phe	Leu	Ser	Ala	Phe	Val	Gly	Asp	Arg	Ile	Thr	Ile	Thr	Cys		
145					150					155					160		
Arg	Ala	Ser	Ser	Gly	Ile	Ser	Arg	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Ala		
				165					170					175			
Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Thr	Leu	Gln		
			180					185					190				
Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe		
		195				200						205					
Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr		



-continued

210	215	220	
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys			
225	230	235	240
Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His			
	245	250	255
 <210> SEQ ID NO 21			
<211> LENGTH: 774			
<212> TYPE: DNA			
<213> ORGANISM: Artificial			
<220> FEATURE:			
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1)..(774)			
<220> FEATURE:			
<221> NAME/KEY: misc_feature			
<222> LOCATION: (85)..(87)			
<223> OTHER INFORMATION: A codon encoding an amino acid other than cysteine			
 <400> SEQUENCE: 21			
atg gcg gaa gtg cag ctg gtt gaa tct ggt gct gaa gtt aaa aaa ccg			48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro			
1	5	10	15
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt nnn atc atc tct			96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser			
	20	25	30
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa			144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu			
	35	40	45
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg			192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro			
	50	55	60
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc			240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr			
	65	70	80
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac			288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr			
	85	90	95
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg			336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp			
	100	105	110
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt			384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly			
	115	120	125
ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc			432
Gly Gly Gly Ser Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser			
	130	135	140
ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc			480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys			
	145	150	155
cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca			528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala			
	165	170	175
ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa			576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln			
	180	185	190
acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc			624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe			
	195	200	205
acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac			672

-continued

---

```

Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
 210                215                220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa      720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
225                230                235                240

gtg gac atc aaa cgc gcg gcc gca ctc gag cac cac cac cac cac cac      768
Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His
                245                250                255

taa taa                                                                774

```

```

<210> SEQ ID NO 22
<211> LENGTH: 256
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(29)
<223> OTHER INFORMATION: The 'Xaa' at location 29 stands for Lys, Asn,
    Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
    Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 22

```

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
 1                5                10                15

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Xaa Ile Ile Ser
                20                25                30

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
 35                40                45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
 50                55                60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
 65                70                75                80

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
 85                90                95

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
 100               105               110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
 115                120                125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
 130                135                140

Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys
 145                150                155                160

Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala
 165                170                175

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
 180                185                190

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
 195                200                205

Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
 210                215                220

Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
 225                230                235                240

Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His
 245                250                255

```

```

<210> SEQ ID NO 23

```



-continued

```

<211> LENGTH: 744
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(744)

<400> SEQUENCE: 23

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg      48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1                    5                10                15

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc atc tct      96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser
                20                25                30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa     144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
                35                40                45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg     192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
                50                55                60

agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc     240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65                70                75                80

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac     288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
                85                90                95

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg     336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
                100               105               110

ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt     384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
                115                120                125

ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc     432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
                130                135                140

ccg agc tcc ctg agc gcg agc gtt ggt gac cgt atc acc att acc tgc     480
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys
145                150                155                160

cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca     528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala
                165                170                175

ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa     576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
                180                185                190

acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc     624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
                195                200                205

acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac     672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
                210                215                220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa     720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
225                230                235                240

gtg gac atc aaa cgc gcg taa taa      744
Val Asp Ile Lys Arg Ala
                245

```

```

<210> SEQ ID NO 24
<211> LENGTH: 246
<212> TYPE: PRT

```

-continued

<213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 24

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser  
 20 25 30  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95  
 Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser  
 130 135 140  
 Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys  
 145 150 155 160  
 Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala  
 165 170 175  
 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
 180 185 190  
 Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
 195 200 205  
 Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
 210 215 220  
 Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
 225 230 235 240  
 Val Asp Ile Lys Arg Ala  
 245

<210> SEQ ID NO 25  
 <211> LENGTH: 744  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(744)

<400> SEQUENCE: 25

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg 48  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15  
 ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc atc tct 96  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser  
 20 25 30  
 tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa 144  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45



-continued

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg	192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc	240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac	288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
ggt ggc ggc agc ggc ggc ggc ggc agc gat att cag atg acc cag agc	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser	
130 135 140	
ccg agc tcc ctg agc gcg agc gtt ggt gac cgt atc acc att acc tgc	480
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys	
145 150 155 160	
cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca	528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	
165 170 175	
ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa	576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	
180 185 190	
acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc	624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe	
195 200 205	
acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac	672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr	
210 215 220	
tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa	720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys	
225 230 235 240	
gtg gac atc aaa cgc gcg taa taa	744
Val Asp Ile Lys Arg Ala	
245	

&lt;210&gt; SEQ ID NO 26

&lt;211&gt; LENGTH: 246

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 26

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser	
20 25 30	
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	

-continued

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser  
 130 135 140  
 Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys  
 145 150 155 160  
 Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala  
 165 170 175  
 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
 180 185 190  
 Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
 195 200 205  
 Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
 210 215 220  
 Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
 225 230 235 240  
 Val Asp Ile Lys Arg Ala  
 245

<210> SEQ ID NO 27  
 <211> LENGTH: 744  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(744)

<400> SEQUENCE: 27

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg 48  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15  
 ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct 96  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser  
 20 25 30  
 tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa 144  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45  
 tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg 192  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60  
 agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc 240  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80  
 gct tac ctg caa tgg agc agc ctg aaa gcg agc gac acc gcg atg tac 288  
 Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95  
 tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg 336  
 Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110  
 ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt 384  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125  
 ggt ggc ggc agc ggc ggc ggc ggc agc gat att cag atg acc cag agc 432  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser  
 130 135 140



-continued

---

```

ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc      480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys
145                      150                      155                      160

cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa aaa      528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys
                      165                      170                      175

ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa      576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
                      180                      185                      190

acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc      624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
                      195                      200                      205

acc ctg acc atc agc agc ctg caa ccg gag gat ttt gcc acc tat tac      672
Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
                      210                      215                      220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa      720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
225                      230                      235                      240

gtg gac atc aaa cgc gcg taa taa      744
Val Asp Ile Lys Arg Ala
                      245

```

```

<210> SEQ ID NO 28
<211> LENGTH: 246
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 28

```

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1                      5                      10                      15

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser
                20                      25                      30

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
                35                      40                      45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
50                      55                      60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65                      70                      75                      80

Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
                85                      90                      95

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
                100                      105                      110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115                      120                      125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser
130                      135                      140

Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys
145                      150                      155                      160

Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys
                165                      170                      175

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
                180                      185                      190

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
195                      200                      205

Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr

```

-continued

210	215	220	
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys			
225	230	235	240
Val Asp Ile Lys Arg Ala			
	245		
<210> SEQ ID NO 29			
<211> LENGTH: 759			
<212> TYPE: DNA			
<213> ORGANISM: Artificial			
<220> FEATURE:			
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1)..(759)			
<400> SEQUENCE: 29			
atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg			48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro			
1	5	10	15
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct			96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser			
	20	25	30
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa			144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu			
	35	40	45
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg			192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro			
	50	55	60
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc			240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr			
65	70	75	80
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac			288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr			
	85	90	95
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg			336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp			
	100	105	110
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt			384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly			
	115	120	125
ggt ggc gga tcc ggt ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt			432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val			
	130	135	140
gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt			480
Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg			
145	150	155	160
atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc tat ctg gcg			528
Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala			
	165	170	175
tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg atc tat gct			576
Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala			
	180	185	190
gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc ggt agc ggc			624
Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly			
	195	200	205
agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa ccg gag gat			672
Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp			
	210	215	220
ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg ctg acc ttc			720
Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe			



-continued

---

225                    230                    235                    240

ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg taa taa                    759  
 Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala  
                   245                    250

<210> SEQ ID NO 30  
 <211> LENGTH: 251  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 30

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1                    5                    10                    15

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser  
                   20                    25                    30

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
                   35                    40                    45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
                   50                    55                    60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65                    70                    75                    80

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
                   85                    90                    95

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
                   100                    105                    110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
                   115                    120                    125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val  
                   130                    135                    140

Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg  
 145                    150                    155                    160

Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala  
                   165                    170                    175

Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala  
                   180                    185                    190

Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly  
                   195                    200                    205

Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp  
                   210                    215                    220

Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe  
 225                    230                    235                    240

Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala  
                   245                    250

<210> SEQ ID NO 31  
 <211> LENGTH: 762  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(762)

<400> SEQUENCE: 31

atg gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt                    48  
 Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val

-continued

1	5	10	15	
ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc				96
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg	20	25	30	
tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg				144
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu	35	40	45	
atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc				192
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser	50	55	60	
ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa				240
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln	65	70	75	80
ccg gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg				288
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro	85	90	95	
ctg acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg agc ggt				336
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly	100	105	110	
ggt ggc ggc agc ggt ggt ggc gga tcc ggt ggt ggc ggc agc ggc ggc				384
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly	115	120	125	
ggc ggc agc gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa				432
Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys	130	135	140	
aaa ccg ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc				480
Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile	145	150	155	160
atc tct tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc				528
Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly	165	170	175	
ctg gaa tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac				576
Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr	180	185	190	
agc ccg agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att				624
Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile	195	200	205	
aac acc gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg				672
Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala	210	215	220	
atg tac tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat				720
Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp	225	230	235	240
tac tgg ggt cag ggc acc ctg gtg acc gtg agc agc taa taa				762
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser	245	250		

&lt;210&gt; SEQ ID NO 32

&lt;211&gt; LENGTH: 252

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 32

Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val	1	5	10	15
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg	20	25	30	
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu				



-continued

35	40	45
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser 50 55 60		
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln 65 70 75 80		
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro 85 90 95		
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly 100 105 110		
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125		
Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys 130 135 140		
Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile 145 150 155 160		
Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly 165 170 175		
Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr 180 185 190		
Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile 195 200 205		
Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala 210 215 220		
Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp 225 230 235 240		
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 245 250		

<210> SEQ ID NO 33  
 <211> LENGTH: 774  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(774)  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (292)..(294)  
 <223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 33

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro 1 5 10 15	48
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser 20 25 30	96
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu 35 40 45	144
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro 50 55 60	192
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr 65 70 75 80	240
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac	288

-continued

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
tac nnn gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Xaa Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
ggc cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
ggc ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser	
130 135 140	
ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc	480
Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys	
145 150 155 160	
cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca	528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	
165 170 175	
ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa	576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	
180 185 190	
acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc	624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe	
195 200 205	
acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac	672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr	
210 215 220	
tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa	720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys	
225 230 235 240	
gtg gac atc aaa cgc gcg gcc gca ctc gag cac cac cac cac cac cac	768
Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His	
245 250 255	
taa taa	774

&lt;210&gt; SEQ ID NO 34

&lt;211&gt; LENGTH: 256

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;222&gt; LOCATION: (98)..(98)

&lt;223&gt; OTHER INFORMATION: The 'Xaa' at location 98 stands for Lys, Asn, Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro, Leu, Tyr, Trp, Cys, or Phe.

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 34

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser	
20 25 30	
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	



-continued

---

Tyr Xaa Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
                   100                                  105                                  110  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
                   115                                  120                                  125  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser  
                   130                                  135                                  140  
 Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys  
                   145                                  150                                  155                                  160  
 Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala  
                                   165                                  170                                  175  
 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
                                   180                                  185                                  190  
 Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
                   195                                  200                                  205  
 Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
                   210                                  215                                  220  
 Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
                   225                                  230                                  235                                  240  
 Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His His His His His His  
                                   245                                  250                                  255

<210> SEQ ID NO 35  
 <211> LENGTH: 744  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(744)

<400> SEQUENCE: 35

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg           48  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
   1                  5                                  10                                  15  
 ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc atc tct           96  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser  
                   20                                  25                                  30  
 tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa           144  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
                   35                                  40                                  45  
 tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg           192  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
                   50                                  55                                  60  
 agc ttt cag ggc cgt gtt acc atc agc gcc gat aaa agc att aac acc           240  
 Ser Phe Gln Gly Arg Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
                   65                                  70                                  75                                  80  
 gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac           288  
 Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
                                   85                                  90                                  95  
 tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg           336  
 Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
                   100                                  105                                  110  
 ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt           384  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
                   115                                  120                                  125  
 ggt ggc ggc agc ggc ggc ggc ggc agc gat att cag atg acc cag agc           432  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser  
                   130                                  135                                  140

-continued

ccg agc tcc ctg agc gcg agc gtt ggt gac cgt atc acc att acc tgc	480
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys	
145 150 155 160	
cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca	528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	
165 170 175	
ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa	576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	
180 185 190	
acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc	624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe	
195 200 205	
acc ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac	672
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr	
210 215 220	
tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa	720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys	
225 230 235 240	
gtg gac atc aaa cgc gcg taa taa	744
Val Asp Ile Lys Arg Ala	
245	

<210> SEQ ID NO 36  
 <211> LENGTH: 246  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 36

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser	
20 25 30	
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
Ser Phe Gln Gly Arg Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser	
130 135 140	
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys	
145 150 155 160	
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala	
165 170 175	
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln	
180 185 190	
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe	
195 200 205	
Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr	
210 215 220	



-continued

Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
225 230 235 240

Val Asp Ile Lys Arg Ala  
245

<210> SEQ ID NO 37

<211> LENGTH: 744

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(744)

<400> SEQUENCE: 37

```

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg      48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1 5 10 15

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc atc tct      96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser
20 25 30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa      144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
35 40 45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg      192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
50 55 60

agc ttt cag ggc cgt gtt acc atc agc gcc gat aaa agc att aac acc      240
Ser Phe Gln Gly Arg Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65 70 75 80

gct tac ctg caa tgg agc agc ctg aaa gcg agc gac acc gcg atg tac      288
Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
85 90 95

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg      336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
100 105 110

ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt      384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125

ggt ggc ggc agc ggc ggc ggc ggc agc gat att cag atg acc cag agc      432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser
130 135 140

ccg agc tcc ctg agc gcg agc gtt ggt gac cgt atc acc att acc tgc      480
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys
145 150 155 160

cgc gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa aaa      528
Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys
165 170 175

ccg ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa      576
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln
180 185 190

acc ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc      624
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
195 200 205

acc ctg acc atc agc agc ctg caa ccg gag gat ttt gcc acc tat tac      672
Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
210 215 220

tgc caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa      720
Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
225 230 235 240

```

-continued

gtg gac atc aaa cgc gcg taa taa  
 Val Asp Ile Lys Arg Ala  
 245

744

<210> SEQ ID NO 38  
 <211> LENGTH: 246  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 38

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser  
 20 25 30  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60  
 Ser Phe Gln Gly Arg Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95  
 Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ser Gly  
 115 120 125  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser  
 130 135 140  
 Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys  
 145 150 155 160  
 Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys  
 165 170 175  
 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln  
 180 185 190  
 Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe  
 195 200 205  
 Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr  
 210 215 220  
 Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys  
 225 230 235 240  
 Val Asp Ile Lys Arg Ala  
 245

<210> SEQ ID NO 39  
 <211> LENGTH: 774  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(774)

<400> SEQUENCE: 39

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15

48



-continued

---

```

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct    96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser
      20                      25                      30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa    144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
      35                      40                      45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg    192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
      50                      55                      60

agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc    240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
      65                      70                      75                      80

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac    288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
      85                      90                      95

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg    336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
      100                      105                      110

ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt    384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
      115                      120                      125

ggt ggc gga tcc ggt ggt ggc ggc tcc ggt ggt ggc ggc agc ggc ggc    432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
      130                      135                      140

ggc ggc agc gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg    480
Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala
      145                      150                      155                      160

ttc gtt ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc    528
Phe Val Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile
      165                      170                      175

agc cgc tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa    576
Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys
      180                      185                      190

ctg ctg atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt    624
Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg
      195                      200                      205

ttt agc ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc    672
Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser
      210                      215                      220

ctg caa ccg gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc    720
Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser
      225                      230                      235                      240

tat ccg ctg acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg    768
Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala
      245                      250                      255

taa taa    774

```

```

<210> SEQ ID NO 40
<211> LENGTH: 256
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 40

```

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1      5      10      15

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser
20     25     30

```

-continued

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly  
 130 135 140

Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala  
 145 150 155 160

Phe Val Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile  
 165 170 175

Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys  
 180 185 190

Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg  
 195 200 205

Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser  
 210 215 220

Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser  
 225 230 235 240

Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala  
 245 250 255

<210> SEQ ID NO 41  
 <211> LENGTH: 789  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(789)

<400> SEQUENCE: 41

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg 48  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct 96  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser  
 20 25 30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa 144  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg 192  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60

agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc 240  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac 288  
 Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95



-continued

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
ggt ggc gga tct ggt ggt ggc ggc agc ggt ggt ggc gga tcc ggt ggt	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly	
130 135 140	
ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc ccg	480
Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro	
145 150 155 160	
agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc cgc	528
Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys Arg	
165 170 175	
gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca ccg	576
Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro	
180 185 190	
ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa acc	624
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr	
195 200 205	
ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc acc	672
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr	
210 215 220	
ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac tgc	720
Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys	
225 230 235 240	
caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa gtg	768
Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val	
245 250 255	
gac atc aaa cgc gcg taa taa	789
Asp Ile Lys Arg Ala	
260	

<210> SEQ ID NO 42  
 <211> LENGTH: 261  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 42

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser	
20 25 30	
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly	

-continued

130	135	140
Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro 145 150 155 160		
Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys Arg 165 170 175		
Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro 180 185 190		
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr 195 200 205		
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 210 215 220		
Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 225 230 235 240		
Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 245 250 255		
Asp Ile Lys Arg Ala 260		

<210> SEQ ID NO 43  
 <211> LENGTH: 777  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(777)

<400> SEQUENCE: 43

atg gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val 1 5 10 15	48
ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg 20 25 30	96
tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45	144
atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser 50 55 60	192
ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln 65 70 75 80	240
ccg gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro 85 90 95	288
ctg acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg agc ggt Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly 100 105 110	336
ggt ggc ggc agc ggt ggt ggc gga tcc ggt ggt ggc ggc tcc ggt ggt Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125	384
ggc ggc agc ggc ggc ggc ggc agc gct gaa gtt caa ctt gtt gaa tct Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser 130 135 140	432
ggt gct gaa gtt aaa aaa ccg ggt gaa tct ctg cgt atc tct tgc aaa Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys 145 150 155 160	480



-continued

ggt tct ggt tgc atc atc tct tct tac tgg atc agc tgg gtt cgt cag	528
Gly Ser Gly Cys Ile Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln	
165 170 175	
atg ccg ggc aag ggc ctg gaa tgg atg ggt aaa att gat ccg ggc gac	576
Met Pro Gly Lys Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp	
180 185 190	
agc tat att aac tac agc ccg agc ttt cag ggc cat gtt acc atc agc	624
Ser Tyr Ile Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser	
195 200 205	
gcc gat aaa agc att aac acc gct tac ctg caa tgg aac agc ctg aaa	672
Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys	
210 215 220	
gcg agc gac acc gcg atg tac tac tgt gcc cgt ggc ggt cgt gac ttc	720
Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe	
225 230 235 240	
ggt gat agc ttc gat tac tgg ggt cag ggc acc ctg gtg acc gtg agc	768
Gly Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser	
245 250 255	
agc taa taa	777
Ser	

<210> SEQ ID NO 44  
 <211> LENGTH: 257  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 44

Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val	
1 5 10 15	
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg	
20 25 30	
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu	
35 40 45	
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser	
50 55 60	
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln	
65 70 75 80	
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro	
85 90 95	
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly	
100 105 110	
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly	
115 120 125	
Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser	
130 135 140	
Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys	
145 150 155 160	
Gly Ser Gly Cys Ile Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln	
165 170 175	
Met Pro Gly Lys Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp	
180 185 190	
Ser Tyr Ile Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser	
195 200 205	
Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys	
210 215 220	

-continued

Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe  
225 230 235 240

Gly Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser  
245 250 255

Ser

&lt;210&gt; SEQ ID NO 45

&lt;211&gt; LENGTH: 792

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Polynucleotide encoding scFv polypeptide

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(792)

&lt;400&gt; SEQUENCE: 45

atg gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt 48  
Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val  
1 5 10 15

ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc 96  
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg  
20 25 30

tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg 144  
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu  
35 40 45

atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc 192  
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser  
50 55 60

ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa 240  
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln  
65 70 75 80

ccg gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg 288  
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro  
85 90 95

ctg acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg agc ggt 336  
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly  
100 105 110

ggt ggc ggc agc ggt ggt ggc gga tct ggt ggt ggc ggc agc ggt ggt 384  
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly  
115 120 125

ggc gga tcc ggt ggt ggc ggc agc ggc ggc ggc ggc agc gct gaa gtt 432  
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu Val  
130 135 140

caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg ggt gaa tct ctg 480  
Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu  
145 150 155 160

cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct tct tac tgg atc 528  
Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser Ser Tyr Trp Ile  
165 170 175

agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa tgg atg ggt aaa 576  
Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Lys  
180 185 190

att gat ccg ggc gac agc tat att aac tac agc ccg agc ttt cag ggc 624  
Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro Ser Phe Gln Gly  
195 200 205

cat gtt acc atc agc gcc gat aaa agc att aac acc gct tac ctg caa 672  
His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln  
210 215 220

tgg aac agc ctg aaa gcg agc gac acc gcg atg tac tac tgt gcc cgt 720  
Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg



-continued

225	230	235	240	
ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg ggt cag ggc acc				768
Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr				
	245	250	255	
ctg gtg acc gtg agc agc taa taa				792
Leu Val Thr Val Ser Ser				
	260			

<210> SEQ ID NO 46  
 <211> LENGTH: 262  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 46

Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val				
1	5	10	15	
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg				
	20	25	30	
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu				
	35	40	45	
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser				
	50	55	60	
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln				
65	70	75	80	
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro				
	85	90	95	
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly				
	100	105	110	
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly				
	115	120	125	
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu Val				
	130	135	140	
Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu				
145	150	155	160	
Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser Ser Tyr Trp Ile				
	165	170	175	
Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Lys				
	180	185	190	
Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro Ser Phe Gln Gly				
	195	200	205	
His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln				
	210	215	220	
Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg				
225	230	235	240	
Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr				
	245	250	255	
Leu Val Thr Val Ser Ser				
	260			

<210> SEQ ID NO 47  
 <211> LENGTH: 759  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:

-continued

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1) .. (759)

&lt;400&gt; SEQUENCE: 47

```

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg      48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1          5          10          15

ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc atc tct      96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser
          20          25          30

tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa      144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
          35          40          45

tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg      192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
          50          55          60

agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc      240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65          70          75          80

gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac      288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
          85          90          95

tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg      336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
          100          105          110

ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt      384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
          115          120          125

ggt ggc gga tcc ggt ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt      432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val
          130          135          140

gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt      480
Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg
145          150          155          160

atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc tat ctg gcg      528
Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala
          165          170          175

tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg atc tat gct      576
Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
          180          185          190

gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc ggt agc ggc      624
Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
          195          200          205

agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa ccg gag gat      672
Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp
          210          215          220

ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg ctg acc ttc      720
Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe
225          230          235          240

ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg taa taa      759
Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala
          245          250

```

&lt;210&gt; SEQ ID NO 48

&lt;211&gt; LENGTH: 251

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 48



-continued

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser  
 20 25 30  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr  
 85 90 95  
 Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp  
 100 105 110  
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val  
 130 135 140  
 Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg  
 145 150 155 160  
 Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala  
 165 170 175  
 Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala  
 180 185 190  
 Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly  
 195 200 205  
 Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp  
 210 215 220  
 Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe  
 225 230 235 240  
 Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala  
 245 250

&lt;210&gt; SEQ ID NO 49

&lt;211&gt; LENGTH: 774

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Polynucleotide encoding scFv polypeptide

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(774)

&lt;400&gt; SEQUENCE: 49

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg 48  
 Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15  
 ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc atc tct 96  
 Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser  
 20 25 30  
 tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa 144  
 Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu  
 35 40 45  
 tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg 192  
 Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro  
 50 55 60  
 agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc 240  
 Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr

-continued

65	70	75	80	
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac				288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	85	90	95	
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg				336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	100	105	110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt				384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	115	120	125	
ggt ggc gga tcc ggt ggt ggc ggc tcc ggt ggt ggc ggc agc ggc ggc				432
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly	130	135	140	
ggc ggc agc gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg				480
Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala	145	150	155	160
ttc gtt ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc				528
Phe Val Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile	165	170	175	
agc cgc tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa				576
Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys	180	185	190	
ctg ctg atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt				624
Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg	195	200	205	
ttt agc ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc				672
Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser	210	215	220	
ctg caa ccg gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc				720
Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser	225	230	235	240
tat ccg ctg acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg				768
Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala	245	250	255	
taa taa				774

<210> SEQ ID NO 50  
 <211> LENGTH: 256  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 50

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	1	5	10	15
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser	20	25	30	
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	35	40	45	
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	50	55	60	
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	65	70	75	80
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	85	90	95	
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	100	105	110	



-continued

Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly
		115					120					125			
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly
		130					135					140			
Gly	Gly	Ser	Asp	Val	Val	Met	Thr	Gln	Ser	Pro	Ser	Phe	Leu	Ser	Ala
145					150					155					160
Phe	Val	Gly	Asp	Arg	Ile	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Ser	Gly	Ile
				165					170					175	
Ser	Arg	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Ala	Pro	Gly	Lys	Ala	Pro	Lys
			180						185					190	
Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Thr	Gly	Val	Pro	Ser	Arg
		195						200				205			
Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Ile	Asn	Ser
	210					215					220				
Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	His	Leu	Asn	Ser
225					230					235					240
Tyr	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Asp	Ile	Lys	Arg	Ala
				245					250					255	

<210> SEQ ID NO 51  
 <211> LENGTH: 789  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(789)

<400> SEQUENCE: 51

atg gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg	48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro	
1 5 10 15	
ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc atc tct	96
Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser	
20 25 30	
tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa	144
Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu	
35 40 45	
tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg	192
Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro	
50 55 60	
agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc	240
Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr	
65 70 75 80	
gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac	288
Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr	
85 90 95	
tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg	336
Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp	
100 105 110	
ggt cag ggc acc ctg gtg acc gtg agc agc ggt ggt ggc ggc agc ggt	384
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ser Gly	
115 120 125	
ggt ggc gga tct ggt ggt ggc ggc agc ggt ggt ggc gga tcc ggt ggt	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly	
130 135 140	
ggc ggc agc ggc ggc ggc ggc agc gat gtt gtg atg acc cag agc ccg	480
Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro	
145 150 155 160	

-continued

---

```

agc ttc ctg agc gcg ttc gtt ggt gac cgt atc acc att acc tgc cgc      528
Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys Arg
      165                      170                      175

gcc agc agc ggc atc agc cgc tat ctg gcg tgg tat cag caa gca ccg      576
Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro
      180                      185                      190

ggt aaa gca ccg aaa ctg ctg atc tat gct gca agc acc ctg caa acc      624
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr
      195                      200                      205

ggc gtt ccg agc cgt ttt agc ggt agc ggc agc ggc acc gag ttc acc      672
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
      210                      215                      220

ctg acc atc aac agc ctg caa ccg gag gat ttt gcc acc tat tac tgc      720
Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
225                      230                      235                      240

caa cac ctg aat agc tat ccg ctg acc ttc ggt ggc ggc acc aaa gtg      768
Gln His Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val
      245                      250                      255

gac atc aaa cgc gcg taa taa      789
Asp Ile Lys Arg Ala
      260

```

```

<210> SEQ ID NO 52
<211> LENGTH: 261
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 52

```

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro
1                      5                      10                      15

Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser
      20                      25                      30

Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
      35                      40                      45

Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro
50                      55                      60

Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr
65                      70                      75                      80

Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
      85                      90                      95

Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp
100                      105                      110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115                      120                      125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
130                      135                      140

Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro
145                      150                      155                      160

Ser Phe Leu Ser Ala Phe Val Gly Asp Arg Ile Thr Ile Thr Cys Arg
      165                      170                      175

Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Ala Pro
      180                      185                      190

Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr
195                      200                      205

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr

```



-continued

210	215	220	
Leu Thr Ile Asn Ser	Leu Gln Pro Glu Asp	Phe Ala Thr Tyr Tyr Cys	
225	230	235	240
Gln His Leu Asn Ser	Tyr Pro Leu Thr Phe	Gly Gly Gly Thr Lys Val	
	245	250	255
Asp Ile Lys Arg Ala			
	260		
<210> SEQ ID NO 53			
<211> LENGTH: 762			
<212> TYPE: DNA			
<213> ORGANISM: Artificial			
<220> FEATURE:			
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1)..(762)			
<400> SEQUENCE: 53			
atg gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt			48
Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val			
1	5	10	15
ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc			96
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg			
	20	25	30
tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg			144
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu			
	35	40	45
atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc			192
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser			
	50	55	60
ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa			240
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln			
65	70	75	80
ccg gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg			288
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro			
	85	90	95
ctg acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg agc ggt			336
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly			
	100	105	110
ggt ggc ggc agc ggt ggt ggc gga tcc ggt ggt ggc ggc agc ggc ggc			384
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly			
	115	120	125
ggc ggc agc gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa			432
Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys			
	130	135	140
aaa ccg ggt gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tat agc			480
Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser			
145	150	155	160
atc tct tct tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc			528
Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly			
	165	170	175
ctg gaa tgg atg ggt aaa att gat ccg ggc gac agc tat att aac tac			576
Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr			
	180	185	190
agc ccg agc ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att			624
Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile			
	195	200	205
aac acc gct tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg			672
Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala			
	210	215	220

-continued

---

```

atg tac tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat      720
Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp
225                230                235                240

```

```

tac tgg ggt cag ggc acc ctg gtg acc gtg agc agc taa taa      762
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                245                250

```

```

<210> SEQ ID NO 54
<211> LENGTH: 252
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 54

```

```

Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val
1          5          10          15

```

```

Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg
                20                25                30

```

```

Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu
35                40                45

```

```

Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser
50                55                60

```

```

Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln
65                70                75                80

```

```

Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro
85                90                95

```

```

Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly
100                105                110

```

```

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
115                120                125

```

```

Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys
130                135                140

```

```

Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser
145                150                155                160

```

```

Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly
165                170                175

```

```

Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr
180                185                190

```

```

Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile
195                200                205

```

```

Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala
210                215                220

```

```

Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp
225                230                235                240

```

```

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                245                250

```

```

<210> SEQ ID NO 55
<211> LENGTH: 777
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(777)

```

```

<400> SEQUENCE: 55

```



-continued

---

```

atg gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt      48
Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val
1           5           10           15

ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc      96
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg
                20           25           30

tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg      144
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu
                35           40           45

atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc      192
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser
                50           55           60

ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa      240
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln
65           70           75           80

ccg gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg      288
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro
                85           90           95

ctg acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg agc ggt      336
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly
                100           105           110

ggt ggc ggc agc ggt ggt ggc gga tcc ggt ggt ggc ggc tcc ggt ggt      384
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
                115           120           125

ggc ggc agc ggc ggc ggc ggc agc gct gaa gtt caa ctt gtt gaa tct      432
Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser
                130           135           140

ggt gct gaa gtt aaa aaa ccg ggt gaa tct ctg cgt atc tct tgc aaa      480
Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys
145           150           155           160

ggt tct ggt tat agc atc tct tct tac tgg atc agc tgg gtt cgt cag      528
Gly Ser Gly Tyr Ser Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln
                165           170           175

atg ccg ggc aag ggc ctg gaa tgg atg ggt aaa att gat ccg ggc gac      576
Met Pro Gly Lys Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp
                180           185           190

agc tat att aac tac agc ccg agc ttt cag ggc cat gtt acc atc agc      624
Ser Tyr Ile Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser
                195           200           205

gcc gat aaa agc att aac acc gct tac ctg caa tgg aac agc ctg aaa      672
Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys
                210           215           220

gcg agc gac acc gcg atg tac tac tgt gcc cgt ggc ggt cgt gac ttc      720
Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe
225           230           235           240

ggt gat agc ttc gat tac tgg ggt cag gcc acc ctg gtg acc gtg agc      768
Gly Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
                245           250           255

agc taa taa
Ser
777

```

```

<210> SEQ ID NO 56
<211> LENGTH: 257
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 56

```

```

Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val

```

-continued

1	5	10	15
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg	20	25	30
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu	35	40	45
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser	50	55	60
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln	65	70	75
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro	85	90	95
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly	100	105	110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly	115	120	125
Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu Val Gln Leu Val Glu Ser	130	135	140
Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys	145	150	155
Gly Ser Gly Tyr Ser Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln	165	170	175
Met Pro Gly Lys Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp	180	185	190
Ser Tyr Ile Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser	195	200	205
Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys	210	215	220
Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe	225	230	235
Gly Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser	245	250	255
Ser			

<210> SEQ ID NO 57  
 <211> LENGTH: 792  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(792)

<400> SEQUENCE: 57

atg gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt	48
Met Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val	
1 5 10 15	
ggt gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc	96
Gly Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg	
20 25 30	
tat ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg	144
Tyr Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu	
35 40 45	
atc tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc	192
Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser	
50 55 60	
ggt agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa	240



-continued

Gly 65	Ser	Gly	Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln		
					70					75					80		
ccg	gag	gat	ttt	gcc	acc	tat	tac	tgc	caa	cac	ctg	aat	agc	tat	ccg		288
Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	His	Leu	Asn	Ser	Tyr	Pro		
			85					90						95			
ctg	acc	ttc	ggt	ggc	ggc	acc	aaa	gtg	gac	atc	aaa	cgc	gcg	agc	ggt		336
Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Asp	Ile	Lys	Arg	Ala	Ser	Gly		
			100					105						110			
ggt	ggc	ggc	agc	ggt	ggc	ggc	gga	tct	ggt	ggt	ggc	ggc	agc	ggt	ggt		384
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly		
			115					120						125			
ggc	gga	tcc	ggt	ggt	ggc	ggc	agc	ggc	ggc	ggc	ggc	agc	gct	gaa	gtt		432
Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ala	Glu	Val		
			130					135						140			
caa	ctt	ggt	gaa	tct	ggt	gct	gaa	ggt	aaa	aaa	ccg	ggt	gaa	tct	ctg		480
Gln	Leu	Val	Glu	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Glu	Ser	Leu		
					150						155				160		
cgt	atc	tct	tgc	aaa	ggt	tct	ggt	tat	agc	atc	tct	tct	tac	tgg	atc		528
Arg	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Ile	Ser	Ser	Tyr	Trp	Ile		
				165					170					175			
agc	tgg	ggt	cgt	cag	atg	ccg	ggc	aag	ggc	ctg	gaa	tgg	atg	ggt	aaa		576
Ser	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly	Lys		
			180					185						190			
att	gat	ccg	ggc	gac	agc	tat	att	aac	tac	agc	ccg	agc	ttt	cag	ggc		624
Ile	Asp	Pro	Gly	Asp	Ser	Tyr	Ile	Asn	Tyr	Ser	Pro	Ser	Phe	Gln	Gly		
			195					200						205			
cat	ggt	acc	atc	agc	gcc	gat	aaa	agc	att	aac	acc	gct	tac	ctg	caa		672
His	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Asn	Thr	Ala	Tyr	Leu	Gln		
			210					215						220			
tgg	aac	agc	ctg	aaa	gcg	agc	gac	acc	gcg	atg	tac	tac	tgt	gcc	cgt		720
Trp	Asn	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg		
			225				230			235				240			
ggc	ggt	cgt	gac	ttc	ggt	gat	agc	ttc	gat	tac	tgg	ggt	cag	ggc	acc		768
Gly	Gly	Arg	Asp	Phe	Gly	Asp	Ser	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr		
				245					250					255			
ctg	gtg	acc	gtg	agc	agc	taa	taa										792
Leu	Val	Thr	Val	Ser	Ser												
			260														

&lt;210&gt; SEQ ID NO 58

&lt;211&gt; LENGTH: 262

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 58

Met	Asp	Val	Val	Met	Thr	Gln	Ser	Pro	Ser	Phe	Leu	Ser	Ala	Phe	Val
1				5					10					15	
Gly	Asp	Arg	Ile	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Ser	Gly	Ile	Ser	Arg
			20					25					30		
Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Ala	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu
		35					40					45			
Ile	Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser
	50					55					60				
Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln
65					70					75					80
Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	His	Leu	Asn	Ser	Tyr	Pro
				85					90					95	

-continued

Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ser Gly  
 100 105 110  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly  
 115 120 125  
 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Ala Glu Val  
 130 135 140  
 Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu  
 145 150 155 160  
 Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Ile Ser Ser Tyr Trp Ile  
 165 170 175  
 Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Lys  
 180 185 190  
 Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro Ser Phe Gln Gly  
 195 200 205  
 His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln  
 210 215 220  
 Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg  
 225 230 235 240  
 Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr  
 245 250 255  
 Leu Val Thr Val Ser Ser  
 260

<210> SEQ ID NO 59  
 <211> LENGTH: 837  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(837)

<400> SEQUENCE: 59

atg aaa tac ctg ctg ccg acc gct gct gct ggt ctg ctg ctc ctc gct 48  
 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala  
 1 5 10 15  
 gcc cag ccg gcg atg gcc gct gaa gtt caa ctt gtt gaa tct ggt gct 96  
 Ala Gln Pro Ala Met Ala Ala Glu Val Gln Leu Val Glu Ser Gly Ala  
 20 25 30  
 gaa gtt aaa aaa ccg ggt gaa tct ctg cgt atc tct tgc aaa ggt tct 144  
 Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser  
 35 40 45  
 ggt tgc atc atc tct tct tac tgg atc agc tgg gtt cgt cag atg ccg 192  
 Gly Cys Ile Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro  
 50 55 60  
 ggc aag ggc ctg gaa tgg atg ggt aaa att gat ccg ggc gac agc tat 240  
 Gly Lys Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr  
 65 70 75 80  
 att aac tac agc ccg agc ttt cag ggc cat gtt acc atc agc gcc gat 288  
 Ile Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp  
 85 90 95  
 aaa agc att aac acc gct tac ctg caa tgg aac agc ctg aaa gcg agc 336  
 Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser  
 100 105 110  
 gac acc gcg atg tac tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat 384  
 Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp  
 115 120 125  
 agc ttc gat tac tgg ggt cag gcc acc ctg gtg acc gtg agc agc ggt 432



-continued

Ser	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly		
130						135					140						
ggt	ggc	ggc	agc	ggt	ggt	ggc	ggc	agc	ggc	ggc	ggc	ggc	agc	gat	gtt		480
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Val		
145					150					155					160		
gtg	atg	acc	cag	agc	ccg	agc	ttc	ctg	agc	gcg	ttc	gtt	ggt	gac	cg		528
Val	Met	Thr	Gln	Ser	Pro	Ser	Phe	Leu	Ser	Ala	Phe	Val	Gly	Asp	Arg		
				165						170					175		
atc	acc	att	acc	tgc	cgc	gcc	agc	agc	ggc	atc	agc	cgc	tat	ctg	gcg		576
Ile	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Ser	Gly	Ile	Ser	Arg	Tyr	Leu	Ala		
			180						185					190			
tgg	tat	cag	caa	gca	ccg	ggt	aaa	gca	ccg	aaa	ctg	ctg	atc	tat	gct		624
Trp	Tyr	Gln	Gln	Ala	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr	Ala		
		195					200						205				
gca	agc	acc	ctg	caa	acc	ggc	ggt	ccg	agc	cgt	ttt	agc	ggt	agc	ggc		672
Ala	Ser	Thr	Leu	Gln	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly		
	210					215					220						
agc	ggc	acc	gag	ttc	acc	ctg	acc	atc	aac	agc	ctg	caa	ccg	gag	gat		720
Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Ile	Asn	Ser	Leu	Gln	Pro	Glu	Asp		
225					230					235					240		
ttt	gcc	acc	tat	tac	tgc	caa	cac	ctg	aat	agc	tat	ccg	ctg	acc	ttc		768
Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	His	Leu	Asn	Ser	Tyr	Pro	Leu	Thr	Phe		
				245					250						255		
ggt	ggc	ggc	acc	aaa	gtg	gac	atc	aaa	cgc	gcg	gcc	gca	ctc	gag	cac		816
Gly	Gly	Gly	Thr	Lys	Val	Asp	Ile	Lys	Arg	Ala	Ala	Ala	Leu	Glu	His		
			260					265					270				
cac	cac	cac	cac	cac	taa	taa											837
His	His	His	His	His													
				275													

&lt;210&gt; SEQ ID NO 60

&lt;211&gt; LENGTH: 277

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 60

Met	Lys	Tyr	Leu	Leu	Pro	Thr	Ala	Ala	Ala	Gly	Leu	Leu	Leu	Leu	Ala		
1				5					10						15		
Ala	Gln	Pro	Ala	Met	Ala	Ala	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Ala		
			20					25						30			
Glu	Val	Lys	Lys	Pro	Gly	Glu	Ser	Leu	Arg	Ile	Ser	Cys	Lys	Gly	Ser		
		35					40					45					
Gly	Cys	Ile	Ile	Ser	Ser	Tyr	Trp	Ile	Ser	Trp	Val	Arg	Gln	Met	Pro		
	50					55					60						
Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly	Lys	Ile	Asp	Pro	Gly	Asp	Ser	Tyr		
65					70					75					80		
Ile	Asn	Tyr	Ser	Pro	Ser	Phe	Gln	Gly	His	Val	Thr	Ile	Ser	Ala	Asp		
				85					90						95		
Lys	Ser	Ile	Asn	Thr	Ala	Tyr	Leu	Gln	Trp	Asn	Ser	Leu	Lys	Ala	Ser		
			100					105						110			
Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Arg	Asp	Phe	Gly	Asp		
		115					120					125					
Ser	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly		
						135						140					
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Val		
145					150						155				160		

-continued

---

Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg  
 165 170 175

Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala  
 180 185 190

Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala  
 195 200 205

Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly  
 210 215 220

Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp  
 225 230 235 240

Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe  
 245 250 255

Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His  
 260 265 270

His His His His His  
 275

<210> SEQ ID NO 61  
 <211> LENGTH: 837  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Polynucleotide encoding scFv polypeptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(837)

<400> SEQUENCE: 61

atg aaa tac ctg ctg ccg acc gct gct gct ggt ctg ctg ctc ctc gct 48  
 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala  
 1 5 10 15

gcc cag ccg gcg atg gcc gct gaa gtt caa ctt gtt gaa tct ggt gct 96  
 Ala Gln Pro Ala Met Ala Ala Glu Val Gln Leu Val Glu Ser Gly Ala  
 20 25 30

gaa gtt aaa aaa ccg ggt gaa tct ctg cgt atc tct tgc aaa ggt tct 144  
 Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser  
 35 40 45

ggt tat atc atc tct tct tac tgg atc agc tgg gtt cgt cag atg ccg 192  
 Gly Tyr Ile Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro  
 50 55 60

ggc aag ggc ctg gaa tgg atg ggt aaa att gat ccg ggc gac agc tat 240  
 Gly Lys Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr  
 65 70 75 80

att aac tac agc ccg agc ttt cag ggc cat gtt acc atc agc gcc gat 288  
 Ile Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp  
 85 90 95

aaa agc att aac acc gct tac ctg caa tgg aac agc ctg aaa gcg agc 336  
 Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser  
 100 105 110

gac acc gcg atg tac tac tgt gcc cgt ggc ggt cgt gac ttc ggt gat 384  
 Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp  
 115 120 125

agc ttc gat tac tgg ggt cag ggc acc ctg gtg acc gtg agc agc ggt 432  
 Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly  
 130 135 140

ggt ggc ggc agc ggt ggt ggc ggc agc ggc ggc ggc ggc agc gat gtt 480  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val  
 145 150 155 160

gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt ggt gac cgt 528  
 Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg



-continued

165	170	175	
atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc tat ctg gcg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala 180 185 190			576
tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg atc tat gct Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala 195 200 205			624
gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc ggt agc ggc Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 210 215 220			672
agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa ccg gag gat Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp 225 230 235 240			720
ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg ctg acc ttc Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe 245 250 255			768
ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg gcc gca ctc gag cac Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His 260 265 270			816
cac cac cac cac cac taa taa His His His His His 275			837

&lt;210&gt; SEQ ID NO 62

&lt;211&gt; LENGTH: 277

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 62

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15
Ala Gln Pro Ala Met Ala Ala Glu Val Gln Leu Val Glu Ser Gly Ala 20 25 30
Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser 35 40 45
Gly Tyr Ile Ile Ser Ser Tyr Trp Ile Ser Trp Val Arg Gln Met Pro 50 55 60
Gly Lys Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr 65 70 75 80
Ile Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp 85 90 95
Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser 100 105 110
Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp 115 120 125
Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly 130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val 145 150 155 160
Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly Asp Arg 165 170 175
Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr Leu Ala 180 185 190
Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala 195 200 205

-continued

Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly  
 210 215 220

Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp  
 225 230 235 240

Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu Thr Phe  
 245 250 255

Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala Leu Glu His  
 260 265 270

His His His His His  
 275

<210> SEQ ID NO 63  
 <211> LENGTH: 363  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: polynucleotide encoding Heavy chain of scFv  
 peptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(363)

<400> SEQUENCE: 63

gct gaa gtt caa ctt gtt gaa tct ggt gct gaa gtt aaa aaa ccg ggt 48  
 Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly  
 1 5 10 15

gaa tct ctg cgt atc tct tgc aaa ggt tct ggt tgc atc atc tct tct 96  
 Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser Ser  
 20 25 30

tac tgg atc agc tgg gtt cgt cag atg ccg ggc aag ggc ctg gaa tgg 144  
 Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp  
 35 40 45

atg ggt aaa att gat ccg ggc gac agc tat att aac tac agc ccg agc 192  
 Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro Ser  
 50 55 60

ttt cag ggc cat gtt acc atc agc gcc gat aaa agc att aac acc gct 240  
 Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala  
 65 70 75 80

tac ctg caa tgg aac agc ctg aaa gcg agc gac acc gcg atg tac tac 288  
 Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr  
 85 90 95

tgt gcc cgt ggc ggt cgt gac ttc ggt gat agc ttc gat tac tgg ggt 336  
 Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp Gly  
 100 105 110

cag ggc acc ctg gtg acc gtg agc agc 363  
 Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> SEQ ID NO 64  
 <211> LENGTH: 121  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 64

Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly  
 1 5 10 15

Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Cys Ile Ile Ser Ser  
 20 25 30

Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp  
 35 40 45



-continued

Met Gly Lys Ile Asp Pro Gly Asp Ser Tyr Ile Asn Tyr Ser Pro Ser  
 50 55 60

Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala  
 65 70 75 80

Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr  
 85 90 95

Cys Ala Arg Gly Gly Arg Asp Phe Gly Asp Ser Phe Asp Tyr Trp Gly  
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> SEQ ID NO 65  
 <211> LENGTH: 327  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: polynucleotide encoding light chain from scFv  
 peptide  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(327)

<400> SEQUENCE: 65

gat gtt gtg atg acc cag agc ccg agc ttc ctg agc gcg ttc gtt ggt 48  
 Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly  
 1 5 10 15

gac cgt atc acc att acc tgc cgc gcc agc agc ggc atc agc cgc tat 96  
 Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr  
 20 25 30

ctg gcg tgg tat cag caa gca ccg ggt aaa gca ccg aaa ctg ctg atc 144  
 Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile  
 35 40 45

tat gct gca agc acc ctg caa acc ggc gtt ccg agc cgt ttt agc ggt 192  
 Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60

agc ggc agc ggc acc gag ttc acc ctg acc atc aac agc ctg caa ccg 240  
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro  
 65 70 75 80

gag gat ttt gcc acc tat tac tgc caa cac ctg aat agc tat ccg ctg 288  
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu  
 85 90 95

acc ttc ggt ggc ggc acc aaa gtg gac atc aaa cgc gcg 327  
 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala  
 100 105

<210> SEQ ID NO 66  
 <211> LENGTH: 109  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 66

Asp Val Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Phe Val Gly  
 1 5 10 15

Asp Arg Ile Thr Ile Thr Cys Arg Ala Ser Ser Gly Ile Ser Arg Tyr  
 20 25 30

Leu Ala Trp Tyr Gln Gln Ala Pro Gly Lys Ala Pro Lys Leu Leu Ile  
 35 40 45

Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60

-continued

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Leu  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Ala  
100 105

<210> SEQ ID NO 67  
<211> LENGTH: 66  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: pelB signal sequence  
<220> FEATURE:  
<221> NAME/KEY: CDS  
<222> LOCATION: (1)..(66)

<400> SEQUENCE: 67

atg aaa tac ctg ctg ccg acc gct gct gct ggt ctg ctg ctc ctc gct 48  
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala  
1 5 10 15

gcc cag ccg gcg atg gcc 66  
Ala Gln Pro Ala Met Ala  
20

<210> SEQ ID NO 68  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 68

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala  
1 5 10 15

Ala Gln Pro Ala Met Ala  
20

<210> SEQ ID NO 69  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Candida albicans

<400> SEQUENCE: 69

Asn Lys Ile Leu Lys Val Ile Arg Lys Asn Ile Val Lys Lys  
1 5 10

<210> SEQ ID NO 70  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Scrambled peptide

<400> SEQUENCE: 70

Ser Phe Lys Trp Gly Val Thr Thr Ser Leu Ser Tyr Phe Pro Lys  
1 5 10 15

<210> SEQ ID NO 71  
<211> LENGTH: 5  
<212> TYPE: PRT  
<213> ORGANISM: artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: scFv linker sequence



-continued

---

<400> SEQUENCE: 71

Gly Gly Gly Gly Ser  
1 5

---

The invention claimed is:

1. A purified scFv peptide comprising a VH domain and a VL domain linked by an amino acid spacer, wherein the V<sub>H</sub> domain comprises the amino acid sequence set forth as SEQ ID NO: 64 and the V<sub>L</sub> domain comprises the amino acid sequence set forth as SEQ ID NO: 66, and wherein the scFv peptide comprises a substitution of an amino acid in the V<sub>H</sub> domain at the position corresponding to C<sub>28</sub> of SEQ ID NO: 64.

2. The scFv peptide according to claim 1, wherein the substitution of the amino acid in the VH domain is C<sub>28</sub>Y.

3. The scFv peptide according to claim 1, wherein the substitution of the amino acid in the V<sub>H</sub> domain is C<sub>28</sub>S.

4. The scFv peptide according to claim 1, further comprising a purification tag.

5. A purified scFv peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:8, 10 and 14, wherein Xaa denotes an amino acid residue other than cysteine and wherein the N-terminal methionine residue may optionally be cleaved off.

6. A pharmaceutical composition comprising the scFv peptide according to claim 1 in combination with a pharmaceutically acceptable excipient, diluent or carrier.

7. The pharmaceutical composition of claim 6 further comprising an antifungal agent.

8. The pharmaceutical composition according to claim 7, wherein the antifungal agent is selected from the group consisting of an azole antifungal agent, a polyene antifungal agent, and an echinocandin antifungal agent.

9. The scFv peptide according to claim 1, wherein the amino acid spacer comprises the sequence (GGGS)<sub>n</sub>, and wherein the integer n is 1 to 12.

10. A pharmaceutical composition comprising the scFv peptide according to claim 9 in combination with a pharmaceutically acceptable excipient, diluent or carrier.

11. A purified scFv peptide comprising the amino acid sequence as set forth as SEQ ID NO: 10, wherein Xaa is tyrosine or serine and wherein the N-terminal methionine residue may optionally be cleaved off.

12. The scFv peptide of claim 11, wherein said scFv peptide is encoded by a nucleic acid sequence having (taa)<sub>2</sub> located at the 3' end of said nucleic acid sequence.

13. The scFv peptide of claim 11, wherein Xaa is serine.

14. The scFv peptide of claim 11, wherein Xaa is tyrosine.

15. The purified peptide according to claim 11, consisting of amino acids 2-256 of SEQ ID NO: 10, wherein Xaa is tyrosine.

16. A pharmaceutical composition comprising the scFv peptide of claim 15 in combination with a pharmaceutically acceptable excipient, diluent or carrier.

17. The pharmaceutical composition according to claim 16, further comprising an antifungal agent.

18. The pharmaceutical composition according to claim 17, wherein the antifungal agent is selected from the group consisting of an azole antifungal agent, a polyene antifungal agent, and an echinocandin antifungal agent.

\* \* \* \* \*